https://trial.medpath.com/news/sanofi-to-present-extensive-immunology-data-at-aaaai-2025-highlighting-dupixent-and-pipeline-advances 2025-02-06T06:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-to-present-extensive-immunology-data-at-aaaai-2025-highlighting-dupixent-and-pipeline-advances 2025-02-06T06:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/sacituzumab-govitecan-shows-promise-in-treating-brain-metastases-and-glioblastoma-in-phase-0-trial 2025-02-06T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sacituzumab-govitecan-shows-promise-in-treating-brain-metastases-and-glioblastoma-in-phase-0-trial 2025-02-06T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/daybue-clinical-trials-show-significant-communication-and-motor-improvements-in-rett-syndrome-patients 2025-02-06T05:58:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daybue-clinical-trials-show-significant-communication-and-motor-improvements-in-rett-syndrome-patients 2025-02-06T05:58:59+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-s-xbb-1-5-based-covid-19-booster-shows-superior-immune-response-in-phase-2-3-trial 2025-02-06T05:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-s-xbb-1-5-based-covid-19-booster-shows-superior-immune-response-in-phase-2-3-trial 2025-02-06T05:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requires-additional-efficacy-study-for-lipocine-s-oral-postpartum-depression-treatment-lpcn-1154 2025-02-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-requires-additional-efficacy-study-for-lipocine-s-oral-postpartum-depression-treatment-lpcn-1154 2025-02-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-announces-2-billion-cost-cutting-plan-amid-patent-cliff-challenges 2025-02-06T04:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-announces-2-billion-cost-cutting-plan-amid-patent-cliff-challenges 2025-02-06T04:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-reports-doubled-q4-profits-driven-by-surging-obesity-and-diabetes-drug-sales 2025-02-06T03:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-reports-doubled-q4-profits-driven-by-surging-obesity-and-diabetes-drug-sales 2025-02-06T03:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-to-present-novel-cancer-research-at-2025-asco-gu-symposium 2025-02-06T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-to-present-novel-cancer-research-at-2025-asco-gu-symposium 2025-02-06T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-antibody-drug-discovery-merging-ai-and-functional-screening-to-unlock-novel-therapeutics 2025-02-06T02:53:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-antibody-drug-discovery-merging-ai-and-functional-screening-to-unlock-novel-therapeutics 2025-02-06T02:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/psm-challenges-hims-hers-super-bowl-ad-for-compounded-semaglutide 2025-02-06T02:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psm-challenges-hims-hers-super-bowl-ad-for-compounded-semaglutide 2025-02-06T02:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/spago-nanomedical-advances-tumorad-program-streamlines-operations-for-clinical-development-focus 2025-02-06T02:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spago-nanomedical-advances-tumorad-program-streamlines-operations-for-clinical-development-focus 2025-02-06T02:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/qlaris-reports-positive-phase-ii-results-for-qls-111-in-reducing-intraocular-pressure 2025-02-06T01:54:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlaris-reports-positive-phase-ii-results-for-qls-111-in-reducing-intraocular-pressure 2025-02-06T01:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-s-rec-994-shows-promising-safety-and-efficacy-signals-in-phase-2-ccm-trial 2025-02-06T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-s-rec-994-shows-promising-safety-and-efficacy-signals-in-phase-2-ccm-trial 2025-02-06T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-secures-15-million-in-direct-offering-to-advance-retinal-disease-therapeutics 2025-02-06T01:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-secures-15-million-in-direct-offering-to-advance-retinal-disease-therapeutics 2025-02-06T01:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-secures-15-million-through-direct-offering-to-advance-tinlarebant-development 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-secures-15-million-through-direct-offering-to-advance-tinlarebant-development 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-therapeutics-advances-phase-3-trials-for-bxcl501-in-agitation-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxcel-therapeutics-advances-phase-3-trials-for-bxcl501-in-agitation-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-and-roche-seek-fda-approval-for-venclexta-gazyva-combination-in-first-line-cll-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-and-roche-seek-fda-approval-for-venclexta-gazyva-combination-in-first-line-cll-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/qureight-s-ai-imaging-platform-to-support-avalyn-s-inhaled-pirfenidone-trial-in-pulmonary-fibrosis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qureight-s-ai-imaging-platform-to-support-avalyn-s-inhaled-pirfenidone-trial-in-pulmonary-fibrosis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mrd-guided-ibrutinib-venetoclax-therapy-shows-superior-outcomes-in-cll-treatment-flair-trial-results 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrd-guided-ibrutinib-venetoclax-therapy-shows-superior-outcomes-in-cll-treatment-flair-trial-results 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-walk-n-watch-protocol-shows-significant-improvements-in-post-stroke-recovery 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-walk-n-watch-protocol-shows-significant-improvements-in-post-stroke-recovery 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enlivex-reports-promising-results-in-phase-i-ii-trial-of-allocetra-for-severe-knee-osteoarthritis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enlivex-reports-promising-results-in-phase-i-ii-trial-of-allocetra-for-severe-knee-osteoarthritis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-appoints-former-novartis-executive-jeffrey-legos-as-chief-oncology-officer-to-strengthen-cancer-drug-portfolio 2025-02-05T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-appoints-former-novartis-executive-jeffrey-legos-as-chief-oncology-officer-to-strengthen-cancer-drug-portfolio 2025-02-05T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/hbm-holdings-secures-nmpa-approval-to-begin-copd-drug-trials-in-china 2025-02-05T23:31:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hbm-holdings-secures-nmpa-approval-to-begin-copd-drug-trials-in-china 2025-02-05T23:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-neurosciences-advances-jotrol-platform-with-phase-2a-parkinson-s-trial-and-consumer-product-launch 2025-02-05T23:31:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jupiter-neurosciences-advances-jotrol-platform-with-phase-2a-parkinson-s-trial-and-consumer-product-launch 2025-02-05T23:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-trial-shows-glp-1-drug-exenatide-ineffective-for-parkinson-s-disease-treatment 2025-02-05T23:01:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-trial-shows-glp-1-drug-exenatide-ineffective-for-parkinson-s-disease-treatment 2025-02-05T23:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/blinklab-launches-fda-registrational-trial-for-ai-powered-autism-diagnostic-tool 2025-02-05T23:01:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinklab-launches-fda-registrational-trial-for-ai-powered-autism-diagnostic-tool 2025-02-05T23:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-launches-ps11m-ai-powered-breast-cancer-screening-trial-involving-700000-women 2025-02-05T23:01:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-launches-ps11m-ai-powered-breast-cancer-screening-trial-involving-700000-women 2025-02-05T23:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-cellular-enabled-sansa-home-sleep-apnea-test-eliminating-need-for-smartphone-apps 2025-02-05T22:30:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-cellular-enabled-sansa-home-sleep-apnea-test-eliminating-need-for-smartphone-apps 2025-02-05T22:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/tinivo-2-trial-shows-no-added-benefit-of-nivolumab-combination-in-io-refractory-rcc-treatment 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tinivo-2-trial-shows-no-added-benefit-of-nivolumab-combination-in-io-refractory-rcc-treatment 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/identiv-and-novanta-partner-to-advance-rfid-technology-in-medical-devices-and-pharmaceuticals 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/identiv-and-novanta-partner-to-advance-rfid-technology-in-medical-devices-and-pharmaceuticals 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/respiratory-function-monitoring-improves-supraglottic-airway-device-placement-in-neonates-study-shows 2025-02-05T21:57:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/respiratory-function-monitoring-improves-supraglottic-airway-device-placement-in-neonates-study-shows 2025-02-05T21:57:46+00:00 hourly 0.9 https://trial.medpath.com/news/duravyu-shows-promising-results-in-phase-2-verona-trial-for-retinal-diseases 2025-02-05T20:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duravyu-shows-promising-results-in-phase-2-verona-trial-for-retinal-diseases 2025-02-05T20:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-status-to-acrivon-s-ai-powered-cancer-diagnostic-platform 2025-02-05T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-status-to-acrivon-s-ai-powered-cancer-diagnostic-platform 2025-02-05T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/usc-secures-10-8m-pcori-grant-to-compare-hip-fracture-surgery-approaches-in-elderly-patients 2025-02-05T20:55:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-secures-10-8m-pcori-grant-to-compare-hip-fracture-surgery-approaches-in-elderly-patients 2025-02-05T20:55:54+00:00 hourly 0.9 https://trial.medpath.com/news/glucotrack-s-novel-implantable-blood-glucose-monitor-shows-promise-in-first-human-trial 2025-02-05T20:01:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucotrack-s-novel-implantable-blood-glucose-monitor-shows-promise-in-first-human-trial 2025-02-05T20:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-neoantigen-vaccine-shows-promise-in-renal-cell-carcinoma-clinical-trial 2025-02-05T19:37:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-neoantigen-vaccine-shows-promise-in-renal-cell-carcinoma-clinical-trial 2025-02-05T19:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-reinforces-strict-controls-on-ketamine-nasal-spray-for-depression-treatment 2025-02-05T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-reinforces-strict-controls-on-ketamine-nasal-spray-for-depression-treatment 2025-02-05T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/blinklab-advances-smartphone-based-autism-diagnostic-tool-with-first-u-s-clinical-trial-site 2025-02-05T18:44:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinklab-advances-smartphone-based-autism-diagnostic-tool-with-first-u-s-clinical-trial-site 2025-02-05T18:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-abu-dhabi-pioneers-first-gcc-breast-cancer-recurrence-trial-with-astrazeneca 2025-02-05T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-abu-dhabi-pioneers-first-gcc-breast-cancer-recurrence-trial-with-astrazeneca 2025-02-05T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/miist-therapeutics-secures-7m-seed-funding-for-ultra-rapid-inhaled-drug-delivery-platform 2025-02-05T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/miist-therapeutics-secures-7m-seed-funding-for-ultra-rapid-inhaled-drug-delivery-platform 2025-02-05T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-amgen-s-obesity-drug-amg-513-trial-on-clinical-hold 2025-02-05T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-amgen-s-obesity-drug-amg-513-trial-on-clinical-hold 2025-02-05T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/macustar-study-validates-novel-endpoints-for-age-related-macular-degeneration-clinical-trials 2025-02-05T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macustar-study-validates-novel-endpoints-for-age-related-macular-degeneration-clinical-trials 2025-02-05T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-seeks-first-japanese-approval-for-geographic-atrophy-treatment-with-avacincaptad-pegol 2025-02-05T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-seeks-first-japanese-approval-for-geographic-atrophy-treatment-with-avacincaptad-pegol 2025-02-05T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/nutrition-platform-fay-secures-50m-series-b-funding-amid-glp-1-weight-loss-drug-boom 2025-02-05T16:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutrition-platform-fay-secures-50m-series-b-funding-amid-glp-1-weight-loss-drug-boom 2025-02-05T16:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-faces-strategic-challenges-as-29-5b-keytruda-patent-cliff-approaches-in-2028 2025-02-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-faces-strategic-challenges-as-29-5b-keytruda-patent-cliff-approaches-in-2028 2025-02-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-spinal-cord-stimulation-shows-promise-in-treating-spinal-muscular-atrophy 2025-02-05T16:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-spinal-cord-stimulation-shows-promise-in-treating-spinal-muscular-atrophy 2025-02-05T16:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-health-canada-clear-alys-pharmaceuticals-aly-101-for-phase-iia-alopecia-areata-trial 2025-02-05T15:38:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-health-canada-clear-alys-pharmaceuticals-aly-101-for-phase-iia-alopecia-areata-trial 2025-02-05T15:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-s-duravyu-shows-promising-results-in-phase-2-dme-trial-with-extended-treatment-duration 2025-02-05T15:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyepoint-s-duravyu-shows-promising-results-in-phase-2-dme-trial-with-extended-treatment-duration 2025-02-05T15:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/e-star-biotech-initiates-phase-2-trial-of-manp-for-resistant-hypertension-treatment 2025-02-05T15:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/e-star-biotech-initiates-phase-2-trial-of-manp-for-resistant-hypertension-treatment 2025-02-05T15:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-expansion-of-decoy20-cancer-immunotherapy-trial 2025-02-05T15:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-expansion-of-decoy20-cancer-immunotherapy-trial 2025-02-05T15:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-acrivon-s-acr-368-oncosignature-test-for-endometrial-cancer 2025-02-05T15:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-acrivon-s-acr-368-oncosignature-test-for-endometrial-cancer 2025-02-05T15:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-partnership-launches-revolutionary-mrna-vaccine-platform-to-boost-african-manufacturing-independence 2025-02-05T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-partnership-launches-revolutionary-mrna-vaccine-platform-to-boost-african-manufacturing-independence 2025-02-05T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-serplulimab-as-first-anti-pd-1-therapy-for-first-line-es-sclc-treatment 2025-02-05T14:32:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-serplulimab-as-first-anti-pd-1-therapy-for-first-line-es-sclc-treatment 2025-02-05T14:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/wandercraft-initiates-landmark-trial-for-hands-free-personal-exoskeleton-in-sci-patients 2025-02-05T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wandercraft-initiates-landmark-trial-for-hands-free-personal-exoskeleton-in-sci-patients 2025-02-05T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/remote-clinical-pharmacists-drive-5-9m-cost-savings-in-community-oncology-study 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-clinical-pharmacists-drive-5-9m-cost-savings-in-community-oncology-study 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-ceo-expresses-confidence-in-medicare-price-negotiations-for-glp-1-drugs 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-ceo-expresses-confidence-in-medicare-price-negotiations-for-glp-1-drugs 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/inspira-technologies-enhances-hyla-blood-sensor-with-ai-powered-oxygenation-monitoring 2025-02-05T13:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inspira-technologies-enhances-hyla-blood-sensor-with-ai-powered-oxygenation-monitoring 2025-02-05T13:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-promise-for-bms-986354-car-t-cell-therapy-in-multiple-myeloma 2025-02-05T13:28:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-promise-for-bms-986354-car-t-cell-therapy-in-multiple-myeloma 2025-02-05T13:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-advances-to-phase-2-trial-of-ampligen-imfinzi-combination-for-late-stage-pancreatic-cancer 2025-02-05T13:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-immunotech-advances-to-phase-2-trial-of-ampligen-imfinzi-combination-for-late-stage-pancreatic-cancer 2025-02-05T13:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/2-million-grant-awarded-to-advance-gene-therapy-trial-for-rare-childhood-blindness 2025-02-05T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2-million-grant-awarded-to-advance-gene-therapy-trial-for-rare-childhood-blindness 2025-02-05T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-baricitinib-as-first-systemic-treatment-for-severe-alopecia-areata-based-on-phase-3-trial-results 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-baricitinib-as-first-systemic-treatment-for-severe-alopecia-areata-based-on-phase-3-trial-results 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-expert-highlights-critical-gaps-in-precision-medicine-implementation-for-cancer-care 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-expert-highlights-critical-gaps-in-precision-medicine-implementation-for-cancer-care 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicaid-cgt-access-model-s-future-uncertain-amid-policy-changes 2025-02-05T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicaid-cgt-access-model-s-future-uncertain-amid-policy-changes 2025-02-05T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-supports-phase-iii-development-of-novel-non-invasive-endometriosis-imaging-test 2025-02-05T12:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-supports-phase-iii-development-of-novel-non-invasive-endometriosis-imaging-test 2025-02-05T12:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-synthetic-lethal-approaches-show-promise-in-targeting-mtap-and-smarca4-mutations-in-lung-cancer 2025-02-05T12:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-synthetic-lethal-approaches-show-promise-in-targeting-mtap-and-smarca4-mutations-in-lung-cancer 2025-02-05T12:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/msd-and-cellbion-partner-to-test-novel-radioligand-immunotherapy-combination-for-advanced-prostate-cancer 2025-02-05T11:25:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msd-and-cellbion-partner-to-test-novel-radioligand-immunotherapy-combination-for-advanced-prostate-cancer 2025-02-05T11:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promise-tislelizumab-plus-chemotherapy-demonstrates-strong-results-in-advanced-gastroesophageal-cancer 2025-02-05T11:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-shows-promise-tislelizumab-plus-chemotherapy-demonstrates-strong-results-in-advanced-gastroesophageal-cancer 2025-02-05T11:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-glucocorticoids-show-no-benefit-for-skin-fibrosis-in-early-systemic-sclerosis-study 2025-02-05T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-glucocorticoids-show-no-benefit-for-skin-fibrosis-in-early-systemic-sclerosis-study 2025-02-05T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/algiax-s-novel-non-opioid-ap-325-shows-promise-in-phase-2a-neuropathic-pain-trial 2025-02-05T10:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algiax-s-novel-non-opioid-ap-325-shows-promise-in-phase-2a-neuropathic-pain-trial 2025-02-05T10:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-backs-durvalumab-for-limited-stage-sclc-following-chemoradiation-success 2025-02-05T10:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-backs-durvalumab-for-limited-stage-sclc-following-chemoradiation-success 2025-02-05T10:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-susvimo-for-diabetic-macular-edema-first-continuous-delivery-ranibizumab-treatment 2025-02-05T10:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-susvimo-for-diabetic-macular-edema-first-continuous-delivery-ranibizumab-treatment 2025-02-05T10:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-for-wiskott-aldrich-syndrome-under-ema-review 2025-02-05T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-for-wiskott-aldrich-syndrome-under-ema-review 2025-02-05T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-neurotherapia-s-phase-2-trial-for-novel-alzheimer-s-drug-ntrx-07 2025-02-05T10:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-neurotherapia-s-phase-2-trial-for-novel-alzheimer-s-drug-ntrx-07 2025-02-05T10:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-completes-enrollment-in-pivotal-teton-1-trial-for-ipf-treatment 2025-02-05T10:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-completes-enrollment-in-pivotal-teton-1-trial-for-ipf-treatment 2025-02-05T10:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-raises-2031-revenue-target-to-ps40-billion-despite-zantac-impact-on-profits 2025-02-05T09:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-raises-2031-revenue-target-to-ps40-billion-despite-zantac-impact-on-profits 2025-02-05T09:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-files-ind-for-novel-bio-hybrid-thyroid-treatment-advancing-cell-pouch-technology-beyond-diabetes 2025-02-05T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sernova-files-ind-for-novel-bio-hybrid-thyroid-treatment-advancing-cell-pouch-technology-beyond-diabetes 2025-02-05T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/turnstone-biologics-halts-tidal-01-development-explores-strategic-alternatives-amid-financial-constraints 2025-02-05T08:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turnstone-biologics-halts-tidal-01-development-explores-strategic-alternatives-amid-financial-constraints 2025-02-05T08:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-to-present-new-pylarify-data-for-early-prostate-cancer-detection-at-asco-gu-2025 2025-02-05T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-to-present-new-pylarify-data-for-early-prostate-cancer-detection-at-asco-gu-2025 2025-02-05T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-clinical-trial-supply-conference-2025-to-focus-on-ai-integration-and-supply-chain-innovation 2025-02-05T08:16:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-clinical-trial-supply-conference-2025-to-focus-on-ai-integration-and-supply-chain-innovation 2025-02-05T08:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-raises-five-year-revenue-target-to-ps40bn-following-strong-specialty-medicines-growth 2025-02-05T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-raises-five-year-revenue-target-to-ps40bn-following-strong-specialty-medicines-growth 2025-02-05T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/viking-therapeutics-advances-novel-oral-glp-1-gip-dual-agonist-vk2735-to-phase-2-trial-for-obesity-treatment 2025-02-05T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viking-therapeutics-advances-novel-oral-glp-1-gip-dual-agonist-vk2735-to-phase-2-trial-for-obesity-treatment 2025-02-05T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-bnct-cancer-treatment-breakthrough-neuboron-medical-group-reports-success-with-first-domestic-system 2025-02-05T07:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-bnct-cancer-treatment-breakthrough-neuboron-medical-group-reports-success-with-first-domestic-system 2025-02-05T07:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-cldn6-targeted-therapies-show-promise-in-advanced-solid-tumors 2025-02-05T06:00:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-cldn6-targeted-therapies-show-promise-in-advanced-solid-tumors 2025-02-05T06:00:02+00:00 hourly 0.9 https://trial.medpath.com/news/global-survey-reveals-critical-knowledge-gaps-in-genetic-testing-for-ovarian-cancer-treatment 2025-02-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-survey-reveals-critical-knowledge-gaps-in-genetic-testing-for-ovarian-cancer-treatment 2025-02-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-raises-2031-sales-target-to-ps40-billion-driven-by-strong-pipeline-progress 2025-02-05T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-raises-2031-sales-target-to-ps40-billion-driven-by-strong-pipeline-progress 2025-02-05T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/diagnos-secures-2-million-in-private-placement-to-advance-ai-based-healthcare-screening-technology 2025-02-05T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagnos-secures-2-million-in-private-placement-to-advance-ai-based-healthcare-screening-technology 2025-02-05T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/lnp-mrna-technology-evolution-and-bioanalytical-advances-reshape-drug-delivery-landscape 2025-02-05T05:13:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lnp-mrna-technology-evolution-and-bioanalytical-advances-reshape-drug-delivery-landscape 2025-02-05T05:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-portfolio-resilience-cancer-and-hiv-gains-offset-rsv-vaccine-decline 2025-02-05T04:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-portfolio-resilience-cancer-and-hiv-gains-offset-rsv-vaccine-decline 2025-02-05T04:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/delveinsight-report-over-50-pipeline-drugs-in-development-for-urothelial-carcinoma-treatment 2025-02-05T04:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delveinsight-report-over-50-pipeline-drugs-in-development-for-urothelial-carcinoma-treatment 2025-02-05T04:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/jabil-expands-pharmaceutical-manufacturing-capabilities-with-strategic-pii-acquisition 2025-02-05T01:41:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jabil-expands-pharmaceutical-manufacturing-capabilities-with-strategic-pii-acquisition 2025-02-05T01:41:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-05T00:43:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-greenlights-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-05T00:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/pathmaker-s-myoregulator-device-for-als-treatment-receives-irb-approval-for-dod-funded-clinical-trial 2025-02-05T00:01:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathmaker-s-myoregulator-device-for-als-treatment-receives-irb-approval-for-dod-funded-clinical-trial 2025-02-05T00:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/divergent-clinical-evidence-submissions-revealed-in-fda-and-ema-cell-and-gene-therapy-approvals 2025-02-05T00:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/divergent-clinical-evidence-submissions-revealed-in-fda-and-ema-cell-and-gene-therapy-approvals 2025-02-05T00:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/alzheon-to-present-phase-3-data-for-novel-apoe4-targeted-alzheimer-s-pill-in-april-2025 2025-02-05T00:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheon-to-present-phase-3-data-for-novel-apoe4-targeted-alzheimer-s-pill-in-april-2025 2025-02-05T00:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/alberta-innovates-awards-600k-grant-to-voyageur-pharmaceuticals-for-advanced-barium-contrast-media-research 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alberta-innovates-awards-600k-grant-to-voyageur-pharmaceuticals-for-advanced-barium-contrast-media-research 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-assisted-physicians-show-enhanced-clinical-decision-making-in-landmark-study 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-assisted-physicians-show-enhanced-clinical-decision-making-in-landmark-study 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/libtayo-becomes-first-eu-approved-immunotherapy-for-advanced-cervical-cancer 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/libtayo-becomes-first-eu-approved-immunotherapy-for-advanced-cervical-cancer 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-withdraws-aduhelm-eu-application-following-regulatory-setback 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-withdraws-aduhelm-eu-application-following-regulatory-setback 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-evolocumab-shows-strong-benefits-for-elderly-ascvd-patients-in-fourier-trial-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-evolocumab-shows-strong-benefits-for-elderly-ascvd-patients-in-fourier-trial-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/coa-unveils-comprehensive-healthcare-reform-plan-to-address-cancer-care-crisis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coa-unveils-comprehensive-healthcare-reform-plan-to-address-cancer-care-crisis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alberta-innovates-awards-600k-grant-to-voyageur-pharmaceuticals-for-advanced-barium-contrast-media-research 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alberta-innovates-awards-600k-grant-to-voyageur-pharmaceuticals-for-advanced-barium-contrast-media-research 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iib-adagio-trial-adavosertib-shows-limited-efficacy-with-high-toxicity-in-uterine-serous-carcinoma 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iib-adagio-trial-adavosertib-shows-limited-efficacy-with-high-toxicity-in-uterine-serous-carcinoma 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/quality-of-life-comparable-between-erleada-combinations-in-advanced-prostate-cancer-treatment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quality-of-life-comparable-between-erleada-combinations-in-advanced-prostate-cancer-treatment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-discontinues-dmd-gene-therapy-programs-takes-170m-impairment-charge 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-discontinues-dmd-gene-therapy-programs-takes-170m-impairment-charge 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-algorithm-successfully-predicts-cancer-outcomes-using-clinical-notes-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-algorithm-successfully-predicts-cancer-outcomes-using-clinical-notes-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-withdraws-aduhelm-eu-application-following-regulatory-setback 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-withdraws-aduhelm-eu-application-following-regulatory-setback 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oct-analysis-reveals-key-predictors-of-visual-recovery-in-macula-off-retinal-detachment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oct-analysis-reveals-key-predictors-of-visual-recovery-in-macula-off-retinal-detachment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-expands-global-reach-for-eylea-biosimilar-through-strategic-partnerships-with-teva-and-lotus-pharmaceutical 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-expands-global-reach-for-eylea-biosimilar-through-strategic-partnerships-with-teva-and-lotus-pharmaceutical 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-pipeline-expansion-in-schizophrenia-treatment-55-companies-developing-60-novel-therapies 2025-02-04T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pipeline-expansion-in-schizophrenia-treatment-55-companies-developing-60-novel-therapies 2025-02-04T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/emyria-reports-significant-mdma-assisted-therapy-benefits-for-ptsd-in-clinical-trial 2025-02-04T23:31:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emyria-reports-significant-mdma-assisted-therapy-benefits-for-ptsd-in-clinical-trial 2025-02-04T23:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-amgen-s-novel-obesity-drug-candidate-amg-513 2025-02-04T22:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-amgen-s-novel-obesity-drug-candidate-amg-513 2025-02-04T22:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reviews-pertuzumab-biosimilar-hlx11-for-her2-positive-breast-cancer-treatment 2025-02-04T22:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reviews-pertuzumab-biosimilar-hlx11-for-her2-positive-breast-cancer-treatment 2025-02-04T22:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-exposure-and-long-covid-treatment 2025-02-04T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-exposure-and-long-covid-treatment 2025-02-04T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-clinical-trials-showcase-growing-promise-of-radiopharmaceutical-cancer-therapy 2025-02-04T21:22:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-clinical-trials-showcase-growing-promise-of-radiopharmaceutical-cancer-therapy 2025-02-04T21:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-to-present-126-week-vision-restoration-data-for-mco-010-gene-therapy-in-retinitis-pigmentosa 2025-02-04T21:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoscope-to-present-126-week-vision-restoration-data-for-mco-010-gene-therapy-in-retinitis-pigmentosa 2025-02-04T21:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/iit-guwahati-pioneers-adaptive-clinical-trial-method-for-personalized-medicine 2025-02-04T20:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iit-guwahati-pioneers-adaptive-clinical-trial-method-for-personalized-medicine 2025-02-04T20:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-04T20:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-04T20:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/next-gen-ozempic-combo-drug-cagrisema-shows-22-7-weight-loss-with-mixed-patient-experiences 2025-02-04T20:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-gen-ozempic-combo-drug-cagrisema-shows-22-7-weight-loss-with-mixed-patient-experiences 2025-02-04T20:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/brolucizumab-shows-promising-one-year-results-in-wet-amd-treatment-regardless-of-prior-therapy 2025-02-04T19:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brolucizumab-shows-promising-one-year-results-in-wet-amd-treatment-regardless-of-prior-therapy 2025-02-04T19:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/trilink-and-aldevron-partner-to-expand-access-to-cleancap-r-mrna-technology-for-therapeutic-development 2025-02-04T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trilink-and-aldevron-partner-to-expand-access-to-cleancap-r-mrna-technology-for-therapeutic-development 2025-02-04T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/zoetis-updates-librela-label-following-reports-of-severe-side-effects-in-dogs 2025-02-04T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoetis-updates-librela-label-following-reports-of-severe-side-effects-in-dogs 2025-02-04T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/world-cancer-day-2025-launches-united-by-unique-campaign-as-nccn-patient-advocates-share-personal-journeys 2025-02-04T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-cancer-day-2025-launches-united-by-unique-campaign-as-nccn-patient-advocates-share-personal-journeys 2025-02-04T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/phasev-and-alimentiv-partner-to-revolutionize-gi-clinical-trials-through-adaptive-design-technology 2025-02-04T15:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phasev-and-alimentiv-partner-to-revolutionize-gi-clinical-trials-through-adaptive-design-technology 2025-02-04T15:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-shows-bacopa-supplement-may-enhance-memory-and-cognitive-function 2025-02-04T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-shows-bacopa-supplement-may-enhance-memory-and-cognitive-function 2025-02-04T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/sparx3-trial-investigates-high-intensity-exercise-s-impact-on-early-stage-parkinson-s-progression 2025-02-04T15:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparx3-trial-investigates-high-intensity-exercise-s-impact-on-early-stage-parkinson-s-progression 2025-02-04T15:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-prevention-trial-launches-to-stop-alzheimer-s-before-symptoms-begin-in-young-adults 2025-02-04T15:02:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-prevention-trial-launches-to-stop-alzheimer-s-before-symptoms-begin-in-young-adults 2025-02-04T15:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/resmed-expert-dr-alison-wimms-joins-incannex-s-osa-clinical-advisory-board-for-ihl-42x-development 2025-02-04T14:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resmed-expert-dr-alison-wimms-joins-incannex-s-osa-clinical-advisory-board-for-ihl-42x-development 2025-02-04T14:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-hyperthyroidism-clinical-trials-landscape-analysis-reveals-key-research-trends-in-2024 2025-02-04T14:01:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-hyperthyroidism-clinical-trials-landscape-analysis-reveals-key-research-trends-in-2024 2025-02-04T14:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/therasyn-bio-and-rubix-ls-launch-joint-venture-to-develop-novel-topical-breast-cancer-therapy 2025-02-04T14:00:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therasyn-bio-and-rubix-ls-launch-joint-venture-to-develop-novel-topical-breast-cancer-therapy 2025-02-04T14:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-launches-first-human-trial-of-zatolmilast-for-jordan-s-syndrome-treatment 2025-02-04T13:54:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-launches-first-human-trial-of-zatolmilast-for-jordan-s-syndrome-treatment 2025-02-04T13:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-hospitalizations-and-disease-duration-emerge-as-major-risk-factors-for-gallstones-in-crohn-s-disease 2025-02-04T13:52:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-hospitalizations-and-disease-duration-emerge-as-major-risk-factors-for-gallstones-in-crohn-s-disease 2025-02-04T13:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/yale-researchers-launch-novel-app-based-intervention-to-combat-hiv-risk-in-chemsex-communities 2025-02-04T13:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-researchers-launch-novel-app-based-intervention-to-combat-hiv-risk-in-chemsex-communities 2025-02-04T13:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-s-depression-drug-navacaprant-fails-phase-iii-trial-triggering-stock-plunge-and-legal-investigation 2025-02-04T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-s-depression-drug-navacaprant-fails-phase-iii-trial-triggering-stock-plunge-and-legal-investigation 2025-02-04T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-and-bayer-launch-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-02-04T12:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-and-bayer-launch-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-02-04T12:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-auron-therapeutics-novel-kat2a-b-degrader-autx-703-for-clinical-trials-in-blood-cancers 2025-02-04T12:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-auron-therapeutics-novel-kat2a-b-degrader-autx-703-for-clinical-trials-in-blood-cancers 2025-02-04T12:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-birmingham-pioneers-personalized-cancer-treatment-approaches-with-novel-diagnostics-and-mrna-vaccines 2025-02-04T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-birmingham-pioneers-personalized-cancer-treatment-approaches-with-novel-diagnostics-and-mrna-vaccines 2025-02-04T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-herbal-amino-acid-supplement-shows-promising-results-in-osteoarthritis-treatment 2025-02-04T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-herbal-amino-acid-supplement-shows-promising-results-in-osteoarthritis-treatment 2025-02-04T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/dr-agarwal-s-healthcare-makes-stock-market-debut-with-muted-expectations-following-ipo 2025-02-04T11:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-agarwal-s-healthcare-makes-stock-market-debut-with-muted-expectations-following-ipo 2025-02-04T11:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/alys-pharmaceuticals-advances-first-genetic-medicine-for-dermatology-with-phase-2a-trial-ind-clearance 2025-02-04T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alys-pharmaceuticals-advances-first-genetic-medicine-for-dermatology-with-phase-2a-trial-ind-clearance 2025-02-04T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-secures-key-senate-committee-support-after-making-vaccine-policy-commitments 2025-02-04T08:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-secures-key-senate-committee-support-after-making-vaccine-policy-commitments 2025-02-04T08:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/prior-cancer-history-associated-with-better-survival-in-metastatic-colorectal-cancer-patients-study-finds 2025-02-04T08:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prior-cancer-history-associated-with-better-survival-in-metastatic-colorectal-cancer-patients-study-finds 2025-02-04T08:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/uganda-launches-groundbreaking-first-ever-ebola-sudan-vaccine-trial-with-who 2025-02-04T06:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uganda-launches-groundbreaking-first-ever-ebola-sudan-vaccine-trial-with-who 2025-02-04T06:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/weight-cycling-in-type-1-diabetes-linked-to-increased-risk-of-kidney-disease-progression 2025-02-04T06:00:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-cycling-in-type-1-diabetes-linked-to-increased-risk-of-kidney-disease-progression 2025-02-04T06:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/pyxis-oncology-expands-pyx-201-clinical-program-with-new-combination-trial-and-monotherapy-cohorts 2025-02-04T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyxis-oncology-expands-pyx-201-clinical-program-with-new-combination-trial-and-monotherapy-cohorts 2025-02-04T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/flagship-backed-omega-therapeutics-files-for-bankruptcy-halts-cancer-drug-development 2025-02-04T04:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flagship-backed-omega-therapeutics-files-for-bankruptcy-halts-cancer-drug-development 2025-02-04T04:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-halts-gardasil-shipments-to-china-amid-demand-slump-abandons-11b-sales-target 2025-02-04T04:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-halts-gardasil-shipments-to-china-amid-demand-slump-abandons-11b-sales-target 2025-02-04T04:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-trial-validates-safety-of-sabr-for-extended-polymetastatic-cancer-treatment 2025-02-04T02:53:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-i-trial-validates-safety-of-sabr-for-extended-polymetastatic-cancer-treatment 2025-02-04T02:53:56+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-biopharma-s-unbuzzdtm-shows-40-faster-alcohol-metabolism-in-clinical-trial 2025-02-04T02:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-biopharma-s-unbuzzdtm-shows-40-faster-alcohol-metabolism-in-clinical-trial 2025-02-04T02:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/valerio-therapeutics-halts-clinical-trials-pivots-to-early-stage-drug-development 2025-02-04T01:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valerio-therapeutics-halts-clinical-trials-pivots-to-early-stage-drug-development 2025-02-04T01:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/wolfe-research-initiates-coverage-on-vera-therapeutics-with-bullish-outlook-on-iga-nephropathy-treatment 2025-02-04T01:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wolfe-research-initiates-coverage-on-vera-therapeutics-with-bullish-outlook-on-iga-nephropathy-treatment 2025-02-04T01:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/axtria-launches-ai-powered-platform-to-revolutionize-clinical-study-report-generation 2025-02-04T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axtria-launches-ai-powered-platform-to-revolutionize-clinical-study-report-generation 2025-02-04T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/world-cancer-day-highlights-critical-need-to-address-oncology-care-disparities 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-cancer-day-highlights-critical-need-to-address-oncology-care-disparities 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lixisenatide-shows-promise-in-slowing-parkinson-s-disease-progression-in-phase-2-trial 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixisenatide-shows-promise-in-slowing-parkinson-s-disease-progression-in-phase-2-trial 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/walking-program-shows-gender-specific-cognitive-benefits-in-older-adults-with-mci 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/walking-program-shows-gender-specific-cognitive-benefits-in-older-adults-with-mci 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verily-and-sosei-heptares-achieve-early-success-in-ai-powered-gpcr-drug-discovery-for-autoimmune-diseases 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verily-and-sosei-heptares-achieve-early-success-in-ai-powered-gpcr-drug-discovery-for-autoimmune-diseases 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mindfulness-program-shows-67-reduction-in-opioid-cravings-in-clinical-trial 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindfulness-program-shows-67-reduction-in-opioid-cravings-in-clinical-trial 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nintedanib-shows-sustained-efficacy-in-slowing-lung-function-decline-in-ssc-ild-patients-over-four-years 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nintedanib-shows-sustained-efficacy-in-slowing-lung-function-decline-in-ssc-ild-patients-over-four-years 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/significant-weight-gain-underreported-in-alk-lung-cancer-patients-on-alecensa-treatment 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/significant-weight-gain-underreported-in-alk-lung-cancer-patients-on-alecensa-treatment 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seagen-secures-2-6b-deal-with-remegen-for-novel-her2-targeting-cancer-drug 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seagen-secures-2-6b-deal-with-remegen-for-novel-her2-targeting-cancer-drug 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-halts-phase-3-fitusiran-trials-due-to-new-safety-concerns-in-hemophilia-studies 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-halts-phase-3-fitusiran-trials-due-to-new-safety-concerns-in-hemophilia-studies 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-shows-promise-in-bcg-unresponsive-bladder-cancer-treatment 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-shows-promise-in-bcg-unresponsive-bladder-cancer-treatment 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sumitomo-s-novel-schizophrenia-drug-ulotaront-fails-to-meet-primary-endpoint-in-phase-3-trials 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sumitomo-s-novel-schizophrenia-drug-ulotaront-fails-to-meet-primary-endpoint-in-phase-3-trials 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dostarlimab-achieves-100-remission-in-small-scale-colorectal-cancer-trial 2025-02-03T23:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dostarlimab-achieves-100-remission-in-small-scale-colorectal-cancer-trial 2025-02-03T23:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/anterogen-s-stem-cell-therapy-allo-asc-sheet-fails-to-meet-primary-endpoint-in-us-phase-2-dfu-trial 2025-02-03T23:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anterogen-s-stem-cell-therapy-allo-asc-sheet-fails-to-meet-primary-endpoint-in-us-phase-2-dfu-trial 2025-02-03T23:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/oral-ketamine-shows-promise-in-reducing-ptsd-symptoms-with-fewer-side-effects 2025-02-03T22:31:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-ketamine-shows-promise-in-reducing-ptsd-symptoms-with-fewer-side-effects 2025-02-03T22:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-first-in-human-trial-of-novel-alopecia-treatment-hcw9302 2025-02-03T22:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-greenlights-first-in-human-trial-of-novel-alopecia-treatment-hcw9302 2025-02-03T22:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/penn-state-launches-landmark-semaglutide-trial-for-outpatient-opioid-use-disorder-treatment 2025-02-03T22:01:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-state-launches-landmark-semaglutide-trial-for-outpatient-opioid-use-disorder-treatment 2025-02-03T22:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/t-dxd-shows-promise-in-her2-ultra-low-breast-cancer-expanding-treatment-horizons 2025-02-03T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t-dxd-shows-promise-in-her2-ultra-low-breast-cancer-expanding-treatment-horizons 2025-02-03T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/median-technologies-ai-powered-lung-cancer-screening-software-achieves-clinical-trial-success 2025-02-03T19:30:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/median-technologies-ai-powered-lung-cancer-screening-software-achieves-clinical-trial-success 2025-02-03T19:30:29+00:00 hourly 0.9 https://trial.medpath.com/news/bevacizumab-plus-pembrolizumab-shows-promise-in-platinum-resistant-nasopharyngeal-cancer 2025-02-03T18:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bevacizumab-plus-pembrolizumab-shows-promise-in-platinum-resistant-nasopharyngeal-cancer 2025-02-03T18:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-revolutionizes-clinical-trials-with-successful-home-based-research-program 2025-02-03T17:41:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-revolutionizes-clinical-trials-with-successful-home-based-research-program 2025-02-03T17:41:49+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-acquires-global-rights-to-imsidolimab-for-gpp-in-50-million-deal-with-anaptysbio 2025-02-03T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-acquires-global-rights-to-imsidolimab-for-gpp-in-50-million-deal-with-anaptysbio 2025-02-03T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/gh-research-s-inhaled-5-meo-dmt-shows-strong-efficacy-in-phase-iib-depression-trial 2025-02-03T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gh-research-s-inhaled-5-meo-dmt-shows-strong-efficacy-in-phase-iib-depression-trial 2025-02-03T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/surmodics-pounce-xl-thrombectomy-system-shows-promise-in-first-clinical-case 2025-02-03T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surmodics-pounce-xl-thrombectomy-system-shows-promise-in-first-clinical-case 2025-02-03T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-cancer-therapies-advances-in-checkpoint-inhibitors-and-personalized-treatment 2025-02-03T15:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-cancer-therapies-advances-in-checkpoint-inhibitors-and-personalized-treatment 2025-02-03T15:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/promising-results-emerge-from-dual-studies-of-blinatumomab-ponatinib-combination-in-acute-lymphoblastic-leukemia 2025-02-03T15:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-results-emerge-from-dual-studies-of-blinatumomab-ponatinib-combination-in-acute-lymphoblastic-leukemia 2025-02-03T15:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pva-enhanced-boron-drug-shows-promise-in-advancing-cancer-treatment 2025-02-03T15:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pva-enhanced-boron-drug-shows-promise-in-advancing-cancer-treatment 2025-02-03T15:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/d-d-pharmatech-completes-enrollment-for-phase-2-mash-trial-of-novel-dual-glp-1-glucagon-agonist-dd01 2025-02-03T14:59:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d-d-pharmatech-completes-enrollment-for-phase-2-mash-trial-of-novel-dual-glp-1-glucagon-agonist-dd01 2025-02-03T14:59:02+00:00 hourly 0.9 https://trial.medpath.com/news/first-welsh-patient-receives-personalized-mrna-cancer-vaccine-in-groundbreaking-trial 2025-02-03T14:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-welsh-patient-receives-personalized-mrna-cancer-vaccine-in-groundbreaking-trial 2025-02-03T14:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-neurosciences-teams-with-catalent-to-manufacture-jotrol-for-parkinson-s-disease-trial 2025-02-03T14:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jupiter-neurosciences-teams-with-catalent-to-manufacture-jotrol-for-parkinson-s-disease-trial 2025-02-03T14:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/exxel-pharma-s-ex937-advances-to-first-human-trials-for-refractory-chronic-cough-treatment 2025-02-03T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exxel-pharma-s-ex937-advances-to-first-human-trials-for-refractory-chronic-cough-treatment 2025-02-03T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/acp-issues-new-treatment-guidelines-for-episodic-migraine-management 2025-02-03T14:00:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acp-issues-new-treatment-guidelines-for-episodic-migraine-management 2025-02-03T14:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-strong-link-between-cardiovascular-disease-and-advanced-breast-cancer-risk 2025-02-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-strong-link-between-cardiovascular-disease-and-advanced-breast-cancer-risk 2025-02-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ngs-guided-treatment-strategy-shows-promise-for-stk11-keap1-mutated-nsclc-patients 2025-02-03T13:59:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ngs-guided-treatment-strategy-shows-promise-for-stk11-keap1-mutated-nsclc-patients 2025-02-03T13:59:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-topical-drug-delivery-systems-show-promise-in-revolutionizing-breast-cancer-treatment 2025-02-03T13:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-topical-drug-delivery-systems-show-promise-in-revolutionizing-breast-cancer-treatment 2025-02-03T13:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-seclidemstat-trial-43-response-rate-observed-in-advanced-blood-cancer-study 2025-02-03T13:23:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-seclidemstat-trial-43-response-rate-observed-in-advanced-blood-cancer-study 2025-02-03T13:23:39+00:00 hourly 0.9 https://trial.medpath.com/news/seastar-medical-secures-6m-funding-to-advance-novel-extracorporeal-inflammation-therapies 2025-02-03T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seastar-medical-secures-6m-funding-to-advance-novel-extracorporeal-inflammation-therapies 2025-02-03T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-partners-with-advanced-clinical-for-pivotal-phase-iii-osteoarthritis-trial 2025-02-03T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-partners-with-advanced-clinical-for-pivotal-phase-iii-osteoarthritis-trial 2025-02-03T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-launches-public-consultation-for-personalized-mrna-cancer-vaccine-regulations 2025-02-03T12:25:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-launches-public-consultation-for-personalized-mrna-cancer-vaccine-regulations 2025-02-03T12:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-advances-phase-i-iia-gene-therapy-trial-for-fabry-disease-following-safety-milestone 2025-02-03T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniqure-advances-phase-i-iia-gene-therapy-trial-for-fabry-disease-following-safety-milestone 2025-02-03T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-reports-promising-phase-1-2-results-for-novel-covid-19-antibody-vyd2311 2025-02-03T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-reports-promising-phase-1-2-results-for-novel-covid-19-antibody-vyd2311 2025-02-03T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-united-therapeutics-xenotransplant-kidney-ind-clinical-trials-set-for-2025 2025-02-03T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-united-therapeutics-xenotransplant-kidney-ind-clinical-trials-set-for-2025 2025-02-03T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/gh-research-s-novel-psychedelic-shows-promising-results-in-treatment-resistant-depression-trial 2025-02-03T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gh-research-s-novel-psychedelic-shows-promising-results-in-treatment-resistant-depression-trial 2025-02-03T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/entrada-therapeutics-receives-uk-approval-to-begin-phase-1-2-trial-in-duchenne-muscular-dystrophy 2025-02-03T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entrada-therapeutics-receives-uk-approval-to-begin-phase-1-2-trial-in-duchenne-muscular-dystrophy 2025-02-03T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/amicus-therapeutics-to-present-extensive-research-on-fabry-and-pompe-diseases-at-worldsymposium-2025 2025-02-03T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amicus-therapeutics-to-present-extensive-research-on-fabry-and-pompe-diseases-at-worldsymposium-2025 2025-02-03T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-disparities-in-hiv-care-new-study-reveals-critical-gaps-and-strategies-for-improving-access 2025-02-03T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-disparities-in-hiv-care-new-study-reveals-critical-gaps-and-strategies-for-improving-access 2025-02-03T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/protalix-s-prx-115-shows-promise-in-phase-i-gout-trial-with-extended-dosing-potential 2025-02-03T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protalix-s-prx-115-shows-promise-in-phase-i-gout-trial-with-extended-dosing-potential 2025-02-03T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-emerges-as-uk-s-leading-clinical-trial-sponsor-with-new-oxford-innovation-center-nearing-completion 2025-02-03T09:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-emerges-as-uk-s-leading-clinical-trial-sponsor-with-new-oxford-innovation-center-nearing-completion 2025-02-03T09:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-industry-maintains-commitment-to-clinical-trial-diversity-despite-political-headwinds 2025-02-03T09:00:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-industry-maintains-commitment-to-clinical-trial-diversity-despite-political-headwinds 2025-02-03T09:00:26+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-secures-8m-cirm-grant-to-advance-gene-therapy-trial-for-rare-heart-condition 2025-02-03T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenaya-therapeutics-secures-8m-cirm-grant-to-advance-gene-therapy-trial-for-rare-heart-condition 2025-02-03T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/aplagon-secures-eur7m-funding-to-advance-novel-thrombo-inflammatory-treatment-into-phase-2a-trials 2025-02-03T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aplagon-secures-eur7m-funding-to-advance-novel-thrombo-inflammatory-treatment-into-phase-2a-trials 2025-02-03T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/nk-cell-therapy-vcb-1102-advances-to-clinical-trial-for-advanced-pancreatic-cancer-treatment 2025-02-03T07:44:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nk-cell-therapy-vcb-1102-advances-to-clinical-trial-for-advanced-pancreatic-cancer-treatment 2025-02-03T07:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-expands-reach-with-strategic-partnerships-in-animal-health-and-breast-cancer-therapeutics 2025-02-03T07:43:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nona-biosciences-expands-reach-with-strategic-partnerships-in-animal-health-and-breast-cancer-therapeutics 2025-02-03T07:43:26+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-advances-novel-adc-cancer-drug-ct-p70-with-fda-ind-filing 2025-02-03T07:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-advances-novel-adc-cancer-drug-ct-p70-with-fda-ind-filing 2025-02-03T07:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/early-stage-snakebite-drug-varespladib-shows-promise-for-pre-hospital-treatment-despite-trial-setback 2025-02-03T07:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-stage-snakebite-drug-varespladib-shows-promise-for-pre-hospital-treatment-despite-trial-setback 2025-02-03T07:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/lancet-commission-charts-global-roadmap-to-transform-breast-cancer-care-and-address-health-inequities 2025-02-03T07:00:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lancet-commission-charts-global-roadmap-to-transform-breast-cancer-care-and-address-health-inequities 2025-02-03T07:00:56+00:00 hourly 0.9 https://trial.medpath.com/news/advancell-secures-112m-in-oversubscribed-series-c-to-advance-radiopharmaceutical-cancer-therapies 2025-02-03T06:45:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancell-secures-112m-in-oversubscribed-series-c-to-advance-radiopharmaceutical-cancer-therapies 2025-02-03T06:45:25+00:00 hourly 0.9 https://trial.medpath.com/news/pmwc-2025-to-address-key-challenges-in-pharmacogenomics-implementation-and-access 2025-02-03T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmwc-2025-to-address-key-challenges-in-pharmacogenomics-implementation-and-access 2025-02-03T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/kenox-and-lactiga-partner-to-develop-first-in-class-mucosal-immunotherapy-for-immunodeficient-patients 2025-02-03T06:20:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kenox-and-lactiga-partner-to-develop-first-in-class-mucosal-immunotherapy-for-immunodeficient-patients 2025-02-03T06:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharmaceuticals-reshape-cancer-treatment-landscape-from-thyroid-to-advanced-prostate-cancer 2025-02-03T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharmaceuticals-reshape-cancer-treatment-landscape-from-thyroid-to-advanced-prostate-cancer 2025-02-03T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/record-breaking-year-for-rare-disease-clinical-trials-as-2021-marks-peak-in-research-activity 2025-02-03T05:02:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/record-breaking-year-for-rare-disease-clinical-trials-as-2021-marks-peak-in-research-activity 2025-02-03T05:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/rakuten-launches-global-phase-iii-trial-of-novel-photoimmunotherapy-for-head-and-neck-cancer 2025-02-03T04:44:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakuten-launches-global-phase-iii-trial-of-novel-photoimmunotherapy-for-head-and-neck-cancer 2025-02-03T04:44:44+00:00 hourly 0.9 https://trial.medpath.com/news/gedatolisib-shows-promising-77-month-overall-survival-in-advanced-breast-cancer-phase-1b-trial 2025-02-03T04:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gedatolisib-shows-promising-77-month-overall-survival-in-advanced-breast-cancer-phase-1b-trial 2025-02-03T04:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/thc-shows-promise-in-managing-agitation-in-alzheimer-s-disease-ctad-trial-reports 2025-02-03T04:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thc-shows-promise-in-managing-agitation-in-alzheimer-s-disease-ctad-trial-reports 2025-02-03T04:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-advances-global-phase-3-trial-for-cancer-vaccine-tedopi 2025-02-03T04:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-advances-global-phase-3-trial-for-cancer-vaccine-tedopi 2025-02-03T04:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-bcl2-inhibitor-combination-shows-promise-against-drug-resistant-dlbcl-with-bcl10-mutations 2025-02-03T04:01:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-btk-bcl2-inhibitor-combination-shows-promise-against-drug-resistant-dlbcl-with-bcl10-mutations 2025-02-03T04:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-amlitelimab-advances-to-long-term-safety-study-for-atopic-dermatitis-treatment-in-india 2025-02-03T04:01:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-amlitelimab-advances-to-long-term-safety-study-for-atopic-dermatitis-treatment-in-india 2025-02-03T04:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/iran-reports-19-7-growth-in-pharmaceutical-exports-advances-in-cell-and-gene-therapy 2025-02-03T04:01:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iran-reports-19-7-growth-in-pharmaceutical-exports-advances-in-cell-and-gene-therapy 2025-02-03T04:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/digoxin-shows-cost-effectiveness-over-beta-blockers-in-heart-failure-treatment-uk-study-finds 2025-02-03T01:35:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digoxin-shows-cost-effectiveness-over-beta-blockers-in-heart-failure-treatment-uk-study-finds 2025-02-03T01:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-s-bnt111-cancer-vaccine-shows-promise-in-advanced-melanoma-phase-2-trial 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-s-bnt111-cancer-vaccine-shows-promise-in-advanced-melanoma-phase-2-trial 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-acquires-ai-pioneer-inka-health-to-transform-cancer-drug-development 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-acquires-ai-pioneer-inka-health-to-transform-cancer-drug-development 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/omega-3-supplementation-shows-promise-in-slowing-biological-aging-clinical-trial-reveals 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omega-3-supplementation-shows-promise-in-slowing-biological-aging-clinical-trial-reveals 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunocore-advances-clinical-pipeline-with-multiple-phase-3-trials-and-new-drug-candidates 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocore-advances-clinical-pipeline-with-multiple-phase-3-trials-and-new-drug-candidates 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-buprenorphine-monthly-injection-trial-launches-in-australia-for-opioid-dependence-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-buprenorphine-monthly-injection-trial-launches-in-australia-for-opioid-dependence-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-discovery-car-molecules-can-transfer-between-t-cells-in-cancer-immunotherapy 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-discovery-car-molecules-can-transfer-between-t-cells-in-cancer-immunotherapy 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucl-repair-with-internal-bracing-shows-faster-recovery-than-traditional-tommy-john-surgery 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucl-repair-with-internal-bracing-shows-faster-recovery-than-traditional-tommy-john-surgery 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-trial-aims-to-optimize-antibiotic-duration-for-ventilator-associated-pneumonia-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-trial-aims-to-optimize-antibiotic-duration-for-ventilator-associated-pneumonia-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-trial-leads-to-complete-response-in-metastatic-prostate-cancer-patient-using-targeted-immunotherapy 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-trial-leads-to-complete-response-in-metastatic-prostate-cancer-patient-using-targeted-immunotherapy 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-clinical-trials-to-evaluate-advanced-cvad-securement-methods-in-pediatric-patients 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-clinical-trials-to-evaluate-advanced-cvad-securement-methods-in-pediatric-patients 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verge-genomics-launches-first-clinical-trial-of-ai-discovered-als-drug-vrg50635 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verge-genomics-launches-first-clinical-trial-of-ai-discovered-als-drug-vrg50635 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-clinical-trial-investigates-impact-of-hydration-in-end-of-life-care-chelsea-ii-study-launches-across-uk 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-clinical-trial-investigates-impact-of-hydration-in-end-of-life-care-chelsea-ii-study-launches-across-uk 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/synlogic-s-novel-probiotic-therapy-shows-promise-in-phase-2-pku-trial-advancing-to-phase-3 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synlogic-s-novel-probiotic-therapy-shows-promise-in-phase-2-pku-trial-advancing-to-phase-3 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ecp-treatment-shows-promising-results-for-steroid-resistant-chronic-gvhd-patients 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ecp-treatment-shows-promising-results-for-steroid-resistant-chronic-gvhd-patients 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/light-trial-pioneers-new-approach-to-glaucoma-and-ocular-hypertension-management 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/light-trial-pioneers-new-approach-to-glaucoma-and-ocular-hypertension-management 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/induction-chemoimmunotherapy-shows-promise-in-unresectable-stage-iii-nsclc-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/induction-chemoimmunotherapy-shows-promise-in-unresectable-stage-iii-nsclc-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-capvaxive-first-adult-specific-21-valent-pneumococcal-vaccine 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-capvaxive-first-adult-specific-21-valent-pneumococcal-vaccine 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hmb-supplementation-shows-promise-in-duchenne-muscular-dystrophy-dogs-improving-activity-and-protein-metabolism 2025-02-02T20:30:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmb-supplementation-shows-promise-in-duchenne-muscular-dystrophy-dogs-improving-activity-and-protein-metabolism 2025-02-02T20:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/pegmolesatide-shows-promise-as-long-acting-anemia-treatment-in-phase-ii-trials-for-ckd-patients 2025-02-02T17:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pegmolesatide-shows-promise-as-long-acting-anemia-treatment-in-phase-ii-trials-for-ckd-patients 2025-02-02T17:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ecg-feature-analysis-reveals-p-wave-changes-as-early-warning-sign-for-atrial-fibrillation 2025-02-02T15:37:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ecg-feature-analysis-reveals-p-wave-changes-as-early-warning-sign-for-atrial-fibrillation 2025-02-02T15:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-blood-test-trial-in-uk-promises-earlier-more-accessible-dementia-diagnosis 2025-02-02T15:03:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-blood-test-trial-in-uk-promises-earlier-more-accessible-dementia-diagnosis 2025-02-02T15:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/fitusiran-shows-promising-results-in-phase-3-trials-for-hemophilia-treatment 2025-02-02T15:02:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fitusiran-shows-promising-results-in-phase-3-trials-for-hemophilia-treatment 2025-02-02T15:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/who-deploys-2160-experimental-sudan-ebolavirus-vaccine-doses-in-uganda-amid-new-outbreak-concerns 2025-02-02T15:02:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-deploys-2160-experimental-sudan-ebolavirus-vaccine-doses-in-uganda-amid-new-outbreak-concerns 2025-02-02T15:02:21+00:00 hourly 0.9 https://trial.medpath.com/news/mobile-vision-pod-innovation-accelerates-corneal-disease-clinical-trial-progress 2025-02-02T15:01:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobile-vision-pod-innovation-accelerates-corneal-disease-clinical-trial-progress 2025-02-02T15:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/novel-statistical-method-enhances-treatment-effect-analysis-in-follicular-lymphoma-study 2025-02-02T15:01:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-statistical-method-enhances-treatment-effect-analysis-in-follicular-lymphoma-study 2025-02-02T15:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/early-exclusive-enteral-feeding-shows-promising-results-in-preterm-infants-clinical-trial-findings 2025-02-02T12:17:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-exclusive-enteral-feeding-shows-promising-results-in-preterm-infants-clinical-trial-findings 2025-02-02T12:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-developments-in-dermatology-psoriasis-alopecia-and-atopic-dermatitis-treatment-advances 2025-02-02T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-developments-in-dermatology-psoriasis-alopecia-and-atopic-dermatitis-treatment-advances 2025-02-02T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-maritide-weight-loss-drug-shows-promise-despite-market-skepticism 2025-02-02T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-maritide-weight-loss-drug-shows-promise-despite-market-skepticism 2025-02-02T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dual-irak4-flt3-inhibitor-emavusertib-shows-promise-in-mds-and-aml-treatment 2025-02-02T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-dual-irak4-flt3-inhibitor-emavusertib-shows-promise-in-mds-and-aml-treatment 2025-02-02T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ayurvedic-supplement-body-revival-shows-promise-in-phase-ii-breast-cancer-trial 2025-02-02T03:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ayurvedic-supplement-body-revival-shows-promise-in-phase-ii-breast-cancer-trial 2025-02-02T03:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-health-crisis-unfolds-as-foreign-aid-pause-disrupts-critical-medical-programs 2025-02-02T00:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-health-crisis-unfolds-as-foreign-aid-pause-disrupts-critical-medical-programs 2025-02-02T00:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/alexion-launches-phase-3-trial-of-ultomiris-for-severe-covid-19-pneumonia 2025-02-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alexion-launches-phase-3-trial-of-ultomiris-for-severe-covid-19-pneumonia 2025-02-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-beyfortus-first-single-dose-rsv-prevention-for-infants 2025-02-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-beyfortus-first-single-dose-rsv-prevention-for-infants 2025-02-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-advances-lassa-fever-vaccine-development-with-250m-cepi-investment-and-multi-country-trials 2025-02-01T22:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-advances-lassa-fever-vaccine-development-with-250m-cepi-investment-and-multi-country-trials 2025-02-01T22:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-s-gbs-drug-trial-data-readout-imminent-stock-surges-50-after-hours 2025-02-01T20:31:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexon-s-gbs-drug-trial-data-readout-imminent-stock-surges-50-after-hours 2025-02-01T20:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/india-eliminates-import-duties-on-36-life-saving-drugs-for-cancer-and-rare-diseases 2025-02-01T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-eliminates-import-duties-on-36-life-saving-drugs-for-cancer-and-rare-diseases 2025-02-01T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-insights-managing-egfr-mutated-nsclc-with-brain-metastases-lessons-from-clinical-practice 2025-02-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-insights-managing-egfr-mutated-nsclc-with-brain-metastases-lessons-from-clinical-practice 2025-02-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-immunotherapy-combinations-show-promise-beyond-pd-1-inhibition-in-advanced-nsclc 2025-02-01T16:18:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-immunotherapy-combinations-show-promise-beyond-pd-1-inhibition-in-advanced-nsclc 2025-02-01T16:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radiotherapy-approaches-show-promise-in-limited-stage-small-cell-lung-cancer-treatment 2025-02-01T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-radiotherapy-approaches-show-promise-in-limited-stage-small-cell-lung-cancer-treatment 2025-02-01T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-expression-levels-show-variable-correlation-with-adc-efficacy-in-ovarian-cancer-treatment 2025-02-01T12:53:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-expression-levels-show-variable-correlation-with-adc-efficacy-in-ovarian-cancer-treatment 2025-02-01T12:53:54+00:00 hourly 0.9 https://trial.medpath.com/news/quality-of-life-measures-gain-critical-importance-in-gynecologic-oncology-care 2025-02-01T12:53:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quality-of-life-measures-gain-critical-importance-in-gynecologic-oncology-care 2025-02-01T12:53:31+00:00 hourly 0.9 https://trial.medpath.com/news/aga-updates-guidelines-for-hepatitis-b-reactivation-prevention-with-risk-stratified-approach 2025-02-01T09:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aga-updates-guidelines-for-hepatitis-b-reactivation-prevention-with-risk-stratified-approach 2025-02-01T09:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-phase-2-trial-of-novel-dengue-treatment-av-1-amid-rising-us-cases 2025-02-01T07:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-launches-phase-2-trial-of-novel-dengue-treatment-av-1-amid-rising-us-cases 2025-02-01T07:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/novel-3d-printed-mouthguard-device-enters-clinical-trial-for-sleep-apnea-treatment 2025-02-01T04:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-3d-printed-mouthguard-device-enters-clinical-trial-for-sleep-apnea-treatment 2025-02-01T04:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-peptide-compounds-promise-weight-loss-benefits-without-ozempic-s-gi-side-effects 2025-02-01T02:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-peptide-compounds-promise-weight-loss-benefits-without-ozempic-s-gi-side-effects 2025-02-01T02:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/uci-researchers-launch-innovative-phase-2-trial-for-advanced-gastric-cancer-treatment 2025-02-01T02:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uci-researchers-launch-innovative-phase-2-trial-for-advanced-gastric-cancer-treatment 2025-02-01T02:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ozempic-for-chronic-kidney-disease-in-type-2-diabetes-patients 2025-02-01T02:04:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ozempic-for-chronic-kidney-disease-in-type-2-diabetes-patients 2025-02-01T02:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-groundbreaking-crispr-gene-therapy-for-severe-sickle-cell-disease-in-england 2025-02-01T02:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-groundbreaking-crispr-gene-therapy-for-severe-sickle-cell-disease-in-england 2025-02-01T02:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-eight-new-medicines-including-cancer-therapies-and-vaccines-for-eu-approval 2025-02-01T02:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-eight-new-medicines-including-cancer-therapies-and-vaccines-for-eu-approval 2025-02-01T02:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-capvaxive-receives-positive-chmp-opinion-for-adult-pneumococcal-disease-prevention-in-eu 2025-02-01T02:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-capvaxive-receives-positive-chmp-opinion-for-adult-pneumococcal-disease-prevention-in-eu 2025-02-01T02:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/chou2-pharma-initiates-pharmacokinetic-study-for-novel-canine-epilepsy-treatment 2025-02-01T02:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chou2-pharma-initiates-pharmacokinetic-study-for-novel-canine-epilepsy-treatment 2025-02-01T02:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-launches-new-phase-3-trial-of-masitinib-for-als-with-enhanced-protocol 2025-02-01T02:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-launches-new-phase-3-trial-of-masitinib-for-als-with-enhanced-protocol 2025-02-01T02:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/novel-group-therapy-shows-promise-in-treating-mental-health-self-stigma-italian-clinical-trial-launches 2025-02-01T02:03:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-group-therapy-shows-promise-in-treating-mental-health-self-stigma-italian-clinical-trial-launches 2025-02-01T02:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-reports-strong-financial-position-with-a-159m-cash-balance-advances-clinical-programs 2025-02-01T02:01:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-reports-strong-financial-position-with-a-159m-cash-balance-advances-clinical-programs 2025-02-01T02:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-early-detection-of-treatment-responsive-rapidly-progressive-dementia 2025-02-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-early-detection-of-treatment-responsive-rapidly-progressive-dementia 2025-02-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/enzyvant-s-rvt-802-receives-landmark-dual-fast-track-status-from-fda-for-complete-digeorge-syndrome 2025-01-31T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enzyvant-s-rvt-802-receives-landmark-dual-fast-track-status-from-fda-for-complete-digeorge-syndrome 2025-01-31T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/bluebird-bio-s-zynteglo-secures-historic-eu-approval-for-beta-thalassemia-gene-therapy 2025-01-31T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluebird-bio-s-zynteglo-secures-historic-eu-approval-for-beta-thalassemia-gene-therapy 2025-01-31T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-approaches-reshape-lymphoma-treatment-landscape-bispecific-antibodies-and-mrd-guided-therapy-show-promise 2025-01-31T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-approaches-reshape-lymphoma-treatment-landscape-bispecific-antibodies-and-mrd-guided-therapy-show-promise 2025-01-31T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardinal-health-launches-navista-alliance-to-strengthen-independent-community-oncology-practices 2025-01-31T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardinal-health-launches-navista-alliance-to-strengthen-independent-community-oncology-practices 2025-01-31T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-pushes-back-phase-3-data-timeline-for-ionis-partnered-cardiac-therapy 2025-01-31T19:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-pushes-back-phase-3-data-timeline-for-ionis-partnered-cardiac-therapy 2025-01-31T19:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fresh-embryo-transfer-shows-superior-results-for-low-prognosis-ivf-patients-chinese-study-finds 2025-01-31T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresh-embryo-transfer-shows-superior-results-for-low-prognosis-ivf-patients-chinese-study-finds 2025-01-31T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-analysis-shows-promise-in-monitoring-daraxonrasib-treatment-response-in-pancreatic-cancer 2025-01-31T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-analysis-shows-promise-in-monitoring-daraxonrasib-treatment-response-in-pancreatic-cancer 2025-01-31T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/livmarli-shows-long-term-efficacy-in-relieving-itch-for-adolescents-with-alagille-syndrome 2025-01-31T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livmarli-shows-long-term-efficacy-in-relieving-itch-for-adolescents-with-alagille-syndrome 2025-01-31T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-s-relabotulinumtoxina-shows-sustained-6-month-efficacy-in-phase-iiib-trial-for-frown-lines 2025-01-31T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-s-relabotulinumtoxina-shows-sustained-6-month-efficacy-in-phase-iiib-trial-for-frown-lines 2025-01-31T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-tropion-lung12-trial-launches-to-evaluate-datroway-for-early-stage-lung-cancer 2025-01-31T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-tropion-lung12-trial-launches-to-evaluate-datroway-for-early-stage-lung-cancer 2025-01-31T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/hypofractionated-partial-breast-irradiation-shows-promising-results-in-early-stage-breast-cancer-trial 2025-01-31T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypofractionated-partial-breast-irradiation-shows-promising-results-in-early-stage-breast-cancer-trial 2025-01-31T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-platform-revolutionizes-cancer-treatment-personalization-through-multi-modal-data-analysis 2025-01-31T16:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-platform-revolutionizes-cancer-treatment-personalization-through-multi-modal-data-analysis 2025-01-31T16:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/cedars-sinai-partners-with-oxford-science-enterprises-to-advance-digital-health-innovation-invests-2m-in-ai-powered-neurology-platform 2025-01-31T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cedars-sinai-partners-with-oxford-science-enterprises-to-advance-digital-health-innovation-invests-2m-in-ai-powered-neurology-platform 2025-01-31T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/fr-alpha-and-b7-h4-expression-found-in-over-80-of-endometrial-cancer-cases-supporting-adc-development 2025-01-31T16:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fr-alpha-and-b7-h4-expression-found-in-over-80-of-endometrial-cancer-cases-supporting-adc-development 2025-01-31T16:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-adcs-show-promise-in-advancing-ovarian-cancer-treatment-options 2025-01-31T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-adcs-show-promise-in-advancing-ovarian-cancer-treatment-options 2025-01-31T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ind-clearance-to-gameto-s-novel-ivf-treatment-fertilo-paving-way-for-phase-3-trials 2025-01-31T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ind-clearance-to-gameto-s-novel-ivf-treatment-fertilo-paving-way-for-phase-3-trials 2025-01-31T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-celltrion-s-avtozma-a-new-tocilizumab-biosimilar-for-multiple-inflammatory-conditions 2025-01-31T13:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-celltrion-s-avtozma-a-new-tocilizumab-biosimilar-for-multiple-inflammatory-conditions 2025-01-31T13:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-discontinues-soticlestat-development-after-failed-phase-iii-epilepsy-trials 2025-01-31T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-discontinues-soticlestat-development-after-failed-phase-iii-epilepsy-trials 2025-01-31T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/united-health-products-advances-fda-application-for-novel-hemostatic-agent-cellustat 2025-01-31T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-health-products-advances-fda-application-for-novel-hemostatic-agent-cellustat 2025-01-31T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/private-equity-hospital-acquisitions-lead-to-declining-patient-care-experience-jama-study-finds 2025-01-31T12:40:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/private-equity-hospital-acquisitions-lead-to-declining-patient-care-experience-jama-study-finds 2025-01-31T12:40:35+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-calgary-launches-validation-study-for-advanced-at-home-hormone-monitoring-device 2025-01-31T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-calgary-launches-validation-study-for-advanced-at-home-hormone-monitoring-device 2025-01-31T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/ppp2r1a-mutations-linked-to-better-survival-in-high-risk-endometrial-cancer-patients-on-immunotherapy 2025-01-31T12:00:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ppp2r1a-mutations-linked-to-better-survival-in-high-risk-endometrial-cancer-patients-on-immunotherapy 2025-01-31T12:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-increased-recovery-risks-for-elderly-and-frail-patients-after-major-gynecologic-cancer-surgery 2025-01-31T11:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-increased-recovery-risks-for-elderly-and-frail-patients-after-major-gynecologic-cancer-surgery 2025-01-31T11:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/mind-medicine-s-mm120-advances-to-phase-3-trials-following-strong-anxiety-treatment-results 2025-01-31T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mind-medicine-s-mm120-advances-to-phase-3-trials-following-strong-anxiety-treatment-results 2025-01-31T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-s-hhs-secretary-confirmation-hearings-reveal-concerning-stance-on-vaccines-and-healthcare-policy 2025-01-31T10:14:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-s-hhs-secretary-confirmation-hearings-reveal-concerning-stance-on-vaccines-and-healthcare-policy 2025-01-31T10:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/germany-overhauls-drug-pricing-system-introduces-confidential-pricing-eliminates-international-reference-pricing 2025-01-31T09:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/germany-overhauls-drug-pricing-system-introduces-confidential-pricing-eliminates-international-reference-pricing 2025-01-31T09:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/supreme-court-to-review-aca-s-no-cost-prep-coverage-mandate-access-to-preventive-care-at-stake 2025-01-31T09:25:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supreme-court-to-review-aca-s-no-cost-prep-coverage-mandate-access-to-preventive-care-at-stake 2025-01-31T09:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-extends-timeline-for-pelacarsen-phase-3-cardiovascular-trial-to-2026 2025-01-31T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-extends-timeline-for-pelacarsen-phase-3-cardiovascular-trial-to-2026 2025-01-31T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/masld-prevalence-in-us-adults-projected-to-rise-to-41-4-by-2050-signaling-major-health-crisis 2025-01-31T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/masld-prevalence-in-us-adults-projected-to-rise-to-41-4-by-2050-signaling-major-health-crisis 2025-01-31T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-different-effects-of-cll-therapies-on-blood-cell-behavior-ibrutinib-shows-promise-in-normalizing-rbc-aggregation 2025-01-31T07:58:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-different-effects-of-cll-therapies-on-blood-cell-behavior-ibrutinib-shows-promise-in-normalizing-rbc-aggregation 2025-01-31T07:58:04+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-achieves-93-8-sensitivity-in-early-colorectal-cancer-detection 2025-01-31T07:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-achieves-93-8-sensitivity-in-early-colorectal-cancer-detection 2025-01-31T07:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/lanifibranor-shows-promise-in-metabolic-liver-disease-treatment-phase-iii-results-expected-2026 2025-01-31T07:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lanifibranor-shows-promise-in-metabolic-liver-disease-treatment-phase-iii-results-expected-2026 2025-01-31T07:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/velocity-clinical-research-partners-with-vct-to-combat-double-enrollment-in-clinical-trials 2025-01-31T07:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/velocity-clinical-research-partners-with-vct-to-combat-double-enrollment-in-clinical-trials 2025-01-31T07:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-decision-support-tool-enhancement-significantly-improves-cancer-biomarker-documentation 2025-01-31T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-decision-support-tool-enhancement-significantly-improves-cancer-biomarker-documentation 2025-01-31T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/experts-to-explore-cell-and-gene-therapy-frontiers-in-rare-disease-treatment-at-upcoming-webinar 2025-01-31T03:34:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-to-explore-cell-and-gene-therapy-frontiers-in-rare-disease-treatment-at-upcoming-webinar 2025-01-31T03:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/cargo-therapeutics-halts-phase-2-firce-1-trial-of-firi-cel-for-large-b-cell-lymphoma-due-to-safety-concerns 2025-01-31T02:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cargo-therapeutics-halts-phase-2-firce-1-trial-of-firi-cel-for-large-b-cell-lymphoma-due-to-safety-concerns 2025-01-31T02:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-healthcare-startups-secure-major-funding-rad-ai-leads-with-60m-series-c-round 2025-01-31T02:00:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-healthcare-startups-secure-major-funding-rad-ai-leads-with-60m-series-c-round 2025-01-31T02:00:24+00:00 hourly 0.9 https://trial.medpath.com/news/study-shows-no-added-benefit-of-combining-chemotherapy-with-pd-1-inhibitors-in-second-line-nsclc-treatment 2025-01-31T00:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-shows-no-added-benefit-of-combining-chemotherapy-with-pd-1-inhibitors-in-second-line-nsclc-treatment 2025-01-31T00:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-molecular-classification-system-for-retroperitoneal-liposarcoma-reveals-two-distinct-prognostic-subtypes 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-molecular-classification-system-for-retroperitoneal-liposarcoma-reveals-two-distinct-prognostic-subtypes 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tensive-secures-eur14m-series-a-funding-for-novel-bio-absorbable-breast-implant-development 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tensive-secures-eur14m-series-a-funding-for-novel-bio-absorbable-breast-implant-development 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-secures-5-8m-cirm-grant-for-pioneering-angelman-syndrome-gene-therapy-research 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-secures-5-8m-cirm-grant-for-pioneering-angelman-syndrome-gene-therapy-research 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/barda-awards-24m-to-advance-crispr-engineered-phage-therapy-for-drug-resistant-utis 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/barda-awards-24m-to-advance-crispr-engineered-phage-therapy-for-drug-resistant-utis 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-expands-clinical-trial-portfolio-with-studies-on-sepsis-coagulopathy-and-obstructive-sleep-apnea 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-expands-clinical-trial-portfolio-with-studies-on-sepsis-coagulopathy-and-obstructive-sleep-apnea 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pulsesight-therapeutics-initiates-clinical-development-of-novel-transferrin-therapy-for-geographic-atrophy 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulsesight-therapeutics-initiates-clinical-development-of-novel-transferrin-therapy-for-geographic-atrophy 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dostarlimab-shows-promise-in-neoadjuvant-treatment-of-dmmr-colorectal-cancer-asco-2024-update 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dostarlimab-shows-promise-in-neoadjuvant-treatment-of-dmmr-colorectal-cancer-asco-2024-update 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-oral-drug-danicopan-receives-chmp-backing-for-pnh-related-anaemia-treatment 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-oral-drug-danicopan-receives-chmp-backing-for-pnh-related-anaemia-treatment 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-monoclonal-antibody-partnerships-surge-with-599-deals-recorded-since-2016 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-monoclonal-antibody-partnerships-surge-with-599-deals-recorded-since-2016 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cargo-therapeutics-firi-cel-phase-2-trial-falls-short-leading-to-major-stock-downgrade 2025-01-30T23:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cargo-therapeutics-firi-cel-phase-2-trial-falls-short-leading-to-major-stock-downgrade 2025-01-30T23:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/mobile-vision-clinics-enable-successful-rare-eye-disease-trial-enrollment-during-pandemic 2025-01-30T22:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobile-vision-clinics-enable-successful-rare-eye-disease-trial-enrollment-during-pandemic 2025-01-30T22:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/koru-medical-partners-on-phase-iii-trial-for-rare-renal-disorder-drug-delivery 2025-01-30T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/koru-medical-partners-on-phase-iii-trial-for-rare-renal-disorder-drug-delivery 2025-01-30T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-symbravo-novel-dual-action-treatment-for-acute-migraine 2025-01-30T22:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-symbravo-novel-dual-action-treatment-for-acute-migraine 2025-01-30T22:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/hookipa-completes-enrollment-in-phase-1b-trial-of-hiv-therapeutic-vaccine-hb-500 2025-01-30T22:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hookipa-completes-enrollment-in-phase-1b-trial-of-hiv-therapeutic-vaccine-hb-500 2025-01-30T22:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-for-chronic-pain-treatment-expands-with-25-drug-candidates-under-development 2025-01-30T22:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-for-chronic-pain-treatment-expands-with-25-drug-candidates-under-development 2025-01-30T22:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/internet-based-cbt-shows-promise-in-treating-ocd-during-covid-19-pandemic 2025-01-30T22:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/internet-based-cbt-shows-promise-in-treating-ocd-during-covid-19-pandemic 2025-01-30T22:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-launches-groundbreaking-trial-combining-paxalisib-with-immunotherapy-for-triple-negative-breast-cancer 2025-01-30T22:01:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-launches-groundbreaking-trial-combining-paxalisib-with-immunotherapy-for-triple-negative-breast-cancer 2025-01-30T22:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/cargo-therapeutics-halts-phase-2-lbcl-trial-due-to-safety-concerns-cuts-workforce-by-50 2025-01-30T21:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cargo-therapeutics-halts-phase-2-lbcl-trial-due-to-safety-concerns-cuts-workforce-by-50 2025-01-30T21:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-initiates-novel-phase-1b-trial-combining-paxalisib-with-immunotherapy-for-advanced-breast-cancer 2025-01-30T21:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-initiates-novel-phase-1b-trial-combining-paxalisib-with-immunotherapy-for-advanced-breast-cancer 2025-01-30T21:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-approves-mandatory-fentanyl-testing-for-truck-drivers-starting-july-2024 2025-01-30T21:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-approves-mandatory-fentanyl-testing-for-truck-drivers-starting-july-2024 2025-01-30T21:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/olutasidenib-plus-azacitidine-shows-promise-in-idh1-mutated-relapsed-refractory-aml 2025-01-30T18:46:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olutasidenib-plus-azacitidine-shows-promise-in-idh1-mutated-relapsed-refractory-aml 2025-01-30T18:46:06+00:00 hourly 0.9 https://trial.medpath.com/news/blinklab-initiates-major-fda-registration-study-for-autism-diagnostic-platform 2025-01-30T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blinklab-initiates-major-fda-registration-study-for-autism-diagnostic-platform 2025-01-30T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mouse-model-and-organoid-program-advance-drug-discovery-for-adult-granulosa-cell-tumors 2025-01-30T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mouse-model-and-organoid-program-advance-drug-discovery-for-adult-granulosa-cell-tumors 2025-01-30T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/affluent-medical-s-artus-urinary-sphincter-advances-to-female-clinical-trials-following-successful-male-study 2025-01-30T17:45:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affluent-medical-s-artus-urinary-sphincter-advances-to-female-clinical-trials-following-successful-male-study 2025-01-30T17:45:06+00:00 hourly 0.9 https://trial.medpath.com/news/ethris-s-inhaled-mrna-therapy-shows-promise-in-phase-1-asthma-trial 2025-01-30T17:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethris-s-inhaled-mrna-therapy-shows-promise-in-phase-1-asthma-trial 2025-01-30T17:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/phase-2-trial-shows-promise-serplulimab-hlx04-combination-safe-for-advanced-liver-cancer 2025-01-30T16:56:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-2-trial-shows-promise-serplulimab-hlx04-combination-safe-for-advanced-liver-cancer 2025-01-30T16:56:44+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-and-beigene-launch-phase-iii-trial-combining-tislelizumab-and-anktiva-for-advanced-nsclc 2025-01-30T16:34:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-and-beigene-launch-phase-iii-trial-combining-tislelizumab-and-anktiva-for-advanced-nsclc 2025-01-30T16:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/peace-3-trial-investigates-enzalutamide-radium-223-combination-for-metastatic-prostate-cancer 2025-01-30T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peace-3-trial-investigates-enzalutamide-radium-223-combination-for-metastatic-prostate-cancer 2025-01-30T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/collision-trial-thermal-ablation-proves-noninferior-to-surgery-for-colorectal-liver-metastases 2025-01-30T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collision-trial-thermal-ablation-proves-noninferior-to-surgery-for-colorectal-liver-metastases 2025-01-30T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/avecho-biotechnology-advances-phase-iii-cbd-insomnia-trial-despite-initial-recruitment-challenges 2025-01-30T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avecho-biotechnology-advances-phase-iii-cbd-insomnia-trial-despite-initial-recruitment-challenges 2025-01-30T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-tool-enhances-genetic-testing-decisions-in-nicu-improving-patient-care-efficiency 2025-01-30T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-tool-enhances-genetic-testing-decisions-in-nicu-improving-patient-care-efficiency 2025-01-30T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-s-sod1-als-gene-therapy-amt-162-advances-to-next-dosing-phase-after-positive-safety-review 2025-01-30T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniqure-s-sod1-als-gene-therapy-amt-162-advances-to-next-dosing-phase-after-positive-safety-review 2025-01-30T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/zipalertinib-shows-promising-results-in-phase-2b-nsclc-trial-cullinan-management-plans-regulatory-filing 2025-01-30T16:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zipalertinib-shows-promising-results-in-phase-2b-nsclc-trial-cullinan-management-plans-regulatory-filing 2025-01-30T16:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-delivery-of-amifostine-shows-promise-in-advancing-pancreatic-cancer-radiation-therapy 2025-01-30T16:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nasal-delivery-of-amifostine-shows-promise-in-advancing-pancreatic-cancer-radiation-therapy 2025-01-30T16:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/ironwood-pharmaceuticals-cuts-50-of-workforce-amid-lower-revenue-projections-focuses-on-apraglutide-development 2025-01-30T15:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ironwood-pharmaceuticals-cuts-50-of-workforce-amid-lower-revenue-projections-focuses-on-apraglutide-development 2025-01-30T15:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/anetumab-ravtansine-plus-bevacizumab-falls-short-against-standard-therapy-in-ovarian-cancer-trial 2025-01-30T15:16:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anetumab-ravtansine-plus-bevacizumab-falls-short-against-standard-therapy-in-ovarian-cancer-trial 2025-01-30T15:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-novel-sublingual-tablet-for-severe-dust-mite-allergy-treatment-on-nhs 2025-01-30T14:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-novel-sublingual-tablet-for-severe-dust-mite-allergy-treatment-on-nhs 2025-01-30T14:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-subtypes-drive-treatment-outcomes-in-stage-iii-endometrial-cancer-canadian-study-shows 2025-01-30T14:42:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-subtypes-drive-treatment-outcomes-in-stage-iii-endometrial-cancer-canadian-study-shows 2025-01-30T14:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/cargo-therapeutics-halts-phase-ii-car-t-trial-due-to-safety-concerns 2025-01-30T14:06:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cargo-therapeutics-halts-phase-ii-car-t-trial-due-to-safety-concerns 2025-01-30T14:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-s-novel-rsv-antiviral-achieves-89-viral-load-reduction-in-phase-ii-trial 2025-01-30T14:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-s-novel-rsv-antiviral-achieves-89-viral-load-reduction-in-phase-ii-trial 2025-01-30T14:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tau-radiotracers-show-superior-performance-in-alzheimer-s-detection-compared-to-fda-approved-tauvid 2025-01-30T14:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tau-radiotracers-show-superior-performance-in-alzheimer-s-detection-compared-to-fda-approved-tauvid 2025-01-30T14:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/texas-oncology-executive-outlines-strategy-for-value-based-cancer-care-integration 2025-01-30T13:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-oncology-executive-outlines-strategy-for-value-based-cancer-care-integration 2025-01-30T13:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/novel-macrophage-based-cancer-immunotherapy-shows-promise-for-solid-tumors 2025-01-30T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-macrophage-based-cancer-immunotherapy-shows-promise-for-solid-tumors 2025-01-30T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/owkin-initiates-phase-i-trial-of-ai-optimized-triple-inhibitor-okn4395-for-solid-tumors 2025-01-30T13:37:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/owkin-initiates-phase-i-trial-of-ai-optimized-triple-inhibitor-okn4395-for-solid-tumors 2025-01-30T13:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/tubulis-initiates-phase-i-iia-trial-of-novel-5t4-targeting-adc-for-advanced-solid-tumors 2025-01-30T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tubulis-initiates-phase-i-iia-trial-of-novel-5t4-targeting-adc-for-advanced-solid-tumors 2025-01-30T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-advances-eye-cancer-treatment-with-novel-drug-trial-and-organoid-research 2025-01-30T13:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-advances-eye-cancer-treatment-with-novel-drug-trial-and-organoid-research 2025-01-30T13:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/inhibikase-halts-parkinson-s-drug-development-following-phase-ii-trial-setback 2025-01-30T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibikase-halts-parkinson-s-drug-development-following-phase-ii-trial-setback 2025-01-30T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/imvax-raises-29m-to-advance-novel-glioblastoma-treatment-through-phase-iib-trial 2025-01-30T12:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imvax-raises-29m-to-advance-novel-glioblastoma-treatment-through-phase-iib-trial 2025-01-30T12:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/alterity-s-ath434-shows-promise-in-phase-2-multiple-system-atrophy-trial-analyst-raises-price-target 2025-01-30T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alterity-s-ath434-shows-promise-in-phase-2-multiple-system-atrophy-trial-analyst-raises-price-target 2025-01-30T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/ethris-reports-successful-phase-1-results-for-novel-nasal-mrna-therapy-eth47-in-asthma-treatment 2025-01-30T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethris-reports-successful-phase-1-results-for-novel-nasal-mrna-therapy-eth47-in-asthma-treatment 2025-01-30T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-rare-disease-drug-development-shows-promise-with-7000-conditions-under-focus 2025-01-30T09:42:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-rare-disease-drug-development-shows-promise-with-7000-conditions-under-focus 2025-01-30T09:42:29+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-clinical-trial-simulations-promise-to-transform-drug-development-process 2025-01-30T09:30:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-clinical-trial-simulations-promise-to-transform-drug-development-process 2025-01-30T09:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/whole-genome-sequencing-shows-promise-in-multiple-myeloma-despite-implementation-challenges 2025-01-30T09:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whole-genome-sequencing-shows-promise-in-multiple-myeloma-despite-implementation-challenges 2025-01-30T09:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-why-children-s-cancer-immunotherapy-differs-from-adults-opening-path-to-precision-medicine 2025-01-30T09:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-why-children-s-cancer-immunotherapy-differs-from-adults-opening-path-to-precision-medicine 2025-01-30T09:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/creative-medical-s-celz-201-ddt-shows-promising-safety-profile-in-phase-1-2-degenerative-disc-disease-trial 2025-01-30T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-medical-s-celz-201-ddt-shows-promising-safety-profile-in-phase-1-2-degenerative-disc-disease-trial 2025-01-30T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-ibd-summit-to-address-precision-medicine-advances-in-drug-development 2025-01-30T08:14:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-ibd-summit-to-address-precision-medicine-advances-in-drug-development 2025-01-30T08:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-study-confirms-causal-link-between-rheumatoid-arthritis-and-increased-fracture-risk 2025-01-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-study-confirms-causal-link-between-rheumatoid-arthritis-and-increased-fracture-risk 2025-01-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/angiodynamics-launches-ambition-btk-trial-to-evaluate-auryon-laser-system-for-critical-limb-ischemia 2025-01-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angiodynamics-launches-ambition-btk-trial-to-evaluate-auryon-laser-system-for-critical-limb-ischemia 2025-01-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/northstrive-biosciences-launches-preclinical-study-of-el-32-probiotic-combined-with-semaglutide-for-obesity-treatment 2025-01-30T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northstrive-biosciences-launches-preclinical-study-of-el-32-probiotic-combined-with-semaglutide-for-obesity-treatment 2025-01-30T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/understanding-long-term-recurrence-risks-in-early-hr-her2-breast-cancer-beyond-nodal-status 2025-01-30T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/understanding-long-term-recurrence-risks-in-early-hr-her2-breast-cancer-beyond-nodal-status 2025-01-30T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regulus-advances-rgls-8429-to-phase-iii-for-polycystic-kidney-disease-following-promising-phase-ib-results 2025-01-30T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulus-advances-rgls-8429-to-phase-iii-for-polycystic-kidney-disease-following-promising-phase-ib-results 2025-01-30T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/endometriosis-pipeline-expands-with-20-novel-therapies-in-development-across-15-companies 2025-01-30T05:04:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endometriosis-pipeline-expands-with-20-novel-therapies-in-development-across-15-companies 2025-01-30T05:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/japan-s-controversial-approval-of-tecovirimat-for-mpox-treatment-despite-failed-clinical-trials 2025-01-30T05:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-s-controversial-approval-of-tecovirimat-for-mpox-treatment-despite-failed-clinical-trials 2025-01-30T05:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/three-novel-9-month-regimens-show-promise-in-drug-resistant-tb-treatment 2025-01-30T05:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-novel-9-month-regimens-show-promise-in-drug-resistant-tb-treatment 2025-01-30T05:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/oncosil-medical-expands-global-reach-with-new-distribution-deals-and-key-regulatory-milestones 2025-01-30T05:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncosil-medical-expands-global-reach-with-new-distribution-deals-and-key-regulatory-milestones 2025-01-30T05:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/60-degrees-pharmaceuticals-advances-arakoda-for-chronic-babesiosis-treatment-with-phase-ii-trial-approval 2025-01-30T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/60-degrees-pharmaceuticals-advances-arakoda-for-chronic-babesiosis-treatment-with-phase-ii-trial-approval 2025-01-30T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-cell-therapies-show-promise-in-relapsed-multiple-myeloma-trials-at-roswell-park 2025-01-30T05:02:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-cell-therapies-show-promise-in-relapsed-multiple-myeloma-trials-at-roswell-park 2025-01-30T05:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/lasofoxifene-shows-promise-in-improving-urogenital-symptoms-for-esr1-mutated-breast-cancer-patients 2025-01-30T05:02:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lasofoxifene-shows-promise-in-improving-urogenital-symptoms-for-esr1-mutated-breast-cancer-patients 2025-01-30T05:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-orthopreserve-s-novel-meniscus-replacement-implant 2025-01-30T03:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-status-to-orthopreserve-s-novel-meniscus-replacement-implant 2025-01-30T03:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/zipalertinib-shows-40-response-rate-in-egfr-exon-20-nsclc-meeting-phase-1-2-trial-endpoint 2025-01-30T03:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zipalertinib-shows-40-response-rate-in-egfr-exon-20-nsclc-meeting-phase-1-2-trial-endpoint 2025-01-30T03:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-heart-patches-show-promise-in-groundbreaking-clinical-trial 2025-01-30T03:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-heart-patches-show-promise-in-groundbreaking-clinical-trial 2025-01-30T03:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/zentalis-cuts-40-workforce-focuses-on-azenosertib-phase-ii-development-in-gynecological-cancers 2025-01-30T03:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zentalis-cuts-40-workforce-focuses-on-azenosertib-phase-ii-development-in-gynecological-cancers 2025-01-30T03:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/regulus-adpkd-drug-farabursen-shows-promise-in-phase-1b-trial-fda-agrees-to-single-pivotal-phase-3-study 2025-01-30T03:31:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulus-adpkd-drug-farabursen-shows-promise-in-phase-1b-trial-fda-agrees-to-single-pivotal-phase-3-study 2025-01-30T03:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/sozinibercept-shows-promise-in-wet-amd-treatment-as-opthea-s-pivotal-trials-progress 2025-01-30T02:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sozinibercept-shows-promise-in-wet-amd-treatment-as-opthea-s-pivotal-trials-progress 2025-01-30T02:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/remedy-pharmaceuticals-to-present-pivotal-cirara-data-for-large-hemispheric-stroke-at-isc-2025 2025-01-30T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remedy-pharmaceuticals-to-present-pivotal-cirara-data-for-large-hemispheric-stroke-at-isc-2025 2025-01-30T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/kashiv-s-orencia-biosimilar-advances-to-phase-iii-following-successful-phase-i-results 2025-01-30T01:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kashiv-s-orencia-biosimilar-advances-to-phase-iii-following-successful-phase-i-results 2025-01-30T01:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-ozempic-approval-for-kidney-disease-and-cardiovascular-risk-reduction 2025-01-30T01:01:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-ozempic-approval-for-kidney-disease-and-cardiovascular-risk-reduction 2025-01-30T01:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-generic-everolimus-for-tuberous-sclerosis-complex-brain-tumors 2025-01-30T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-generic-everolimus-for-tuberous-sclerosis-complex-brain-tumors 2025-01-30T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-bio-s-novel-car-t-therapy-equecabtagene-autoleucel-under-review-in-singapore-for-multiple-myeloma-treatment 2025-01-30T01:01:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iaso-bio-s-novel-car-t-therapy-equecabtagene-autoleucel-under-review-in-singapore-for-multiple-myeloma-treatment 2025-01-30T01:01:10+00:00 hourly 0.9 https://trial.medpath.com/news/hvivo-expands-european-presence-with-eur10m-acquisition-of-crs-clinical-research-units 2025-01-30T00:31:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hvivo-expands-european-presence-with-eur10m-acquisition-of-crs-clinical-research-units 2025-01-30T00:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/opthea-s-opt-302-eye-disease-treatment-shows-promise-as-phase-iii-trials-progress 2025-01-30T00:01:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opthea-s-opt-302-eye-disease-treatment-shows-promise-as-phase-iii-trials-progress 2025-01-30T00:01:47+00:00 hourly 0.9 https://trial.medpath.com/news/vaxcyte-s-31-strain-pneumococcal-vaccine-shows-superior-immune-response-over-prevnar-20-in-phase-1-2-trial 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxcyte-s-31-strain-pneumococcal-vaccine-shows-superior-immune-response-over-prevnar-20-in-phase-1-2-trial 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-analysis-reveals-20-drug-candidates-for-c-met-nsclc-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-analysis-reveals-20-drug-candidates-for-c-met-nsclc-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aduro-clean-technologies-patents-novel-process-design-for-plastic-recycling-technology 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aduro-clean-technologies-patents-novel-process-design-for-plastic-recycling-technology 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dental-flossing-associated-with-22-lower-stroke-risk-and-reduced-afib-in-25-year-study 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dental-flossing-associated-with-22-lower-stroke-risk-and-reduced-afib-in-25-year-study 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cargo-therapeutics-halts-car-t-development-after-safety-concerns-announces-50-staff-reduction 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cargo-therapeutics-halts-car-t-development-after-safety-concerns-announces-50-staff-reduction 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-emergency-use-authorization-to-lilly-s-bebtelovimab-for-covid-19-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-emergency-use-authorization-to-lilly-s-bebtelovimab-for-covid-19-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-analysis-reveals-75-drug-candidates-in-development-for-advanced-cervical-cancer-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-analysis-reveals-75-drug-candidates-in-development-for-advanced-cervical-cancer-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-analysis-reveals-75-drug-candidates-in-development-for-advanced-cervical-cancer-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-analysis-reveals-75-drug-candidates-in-development-for-advanced-cervical-cancer-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-checkpoint-s-cosibelimab-in-advanced-skin-cancer 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-checkpoint-s-cosibelimab-in-advanced-skin-cancer 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rmat-designation-to-beacon-s-gene-therapy-for-x-linked-retinitis-pigmentosa 2025-01-29T23:02:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rmat-designation-to-beacon-s-gene-therapy-for-x-linked-retinitis-pigmentosa 2025-01-29T23:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-shows-pet-guided-treatment-success-in-early-stage-hodgkin-lymphoma 2025-01-29T23:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-study-shows-pet-guided-treatment-success-in-early-stage-hodgkin-lymphoma 2025-01-29T23:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/promis-neurosciences-to-present-latest-developments-in-neurodegenerative-disease-programs-at-guggenheim-biotech-conference 2025-01-29T23:01:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promis-neurosciences-to-present-latest-developments-in-neurodegenerative-disease-programs-at-guggenheim-biotech-conference 2025-01-29T23:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-terminates-phase-ii-volenrelaxin-trial-in-chronic-kidney-disease 2025-01-29T23:01:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-terminates-phase-ii-volenrelaxin-trial-in-chronic-kidney-disease 2025-01-29T23:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/propheci-trial-launches-to-test-pyrophosphate-treatment-for-rare-calcification-disorder-pxe 2025-01-29T23:01:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/propheci-trial-launches-to-test-pyrophosphate-treatment-for-rare-calcification-disorder-pxe 2025-01-29T23:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/global-gamma-delta-t-cell-therapy-pipeline-expands-with-over-30-cancer-treatments-in-development 2025-01-29T22:01:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-gamma-delta-t-cell-therapy-pipeline-expands-with-over-30-cancer-treatments-in-development 2025-01-29T22:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/study-shows-decentralized-clinical-trials-enhance-demographic-diversity-in-patient-enrollment 2025-01-29T22:01:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-shows-decentralized-clinical-trials-enhance-demographic-diversity-in-patient-enrollment 2025-01-29T22:01:31+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-morning-after-pill-ingredient-ulipristal-acetate-can-induce-abortions 2025-01-29T21:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-morning-after-pill-ingredient-ulipristal-acetate-can-induce-abortions 2025-01-29T21:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiomyopathy-market-projected-to-reach-20-billion-by-2035-as-novel-therapies-advance-through-clinical-development 2025-01-29T18:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiomyopathy-market-projected-to-reach-20-billion-by-2035-as-novel-therapies-advance-through-clinical-development 2025-01-29T18:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/nice-discontinues-review-of-lenvatinib-pembrolizumab-combination-for-advanced-endometrial-cancer 2025-01-29T17:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-discontinues-review-of-lenvatinib-pembrolizumab-combination-for-advanced-endometrial-cancer 2025-01-29T17:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/next-life-sciences-secures-200k-grant-to-advance-novel-male-contraceptive-hydrogel 2025-01-29T17:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-life-sciences-secures-200k-grant-to-advance-novel-male-contraceptive-hydrogel 2025-01-29T17:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/regulus-therapeutics-reports-mixed-results-for-adpkd-program-shares-drop-24 2025-01-29T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulus-therapeutics-reports-mixed-results-for-adpkd-program-shares-drop-24 2025-01-29T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-collaboratory-launches-arbor-telehealth-trial-to-transform-rural-back-pain-care 2025-01-29T16:44:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-collaboratory-launches-arbor-telehealth-trial-to-transform-rural-back-pain-care 2025-01-29T16:44:56+00:00 hourly 0.9 https://trial.medpath.com/news/novel-tad-sie-algorithm-shows-promise-in-optimizing-clinical-trial-sample-sizes 2025-01-29T16:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-tad-sie-algorithm-shows-promise-in-optimizing-clinical-trial-sample-sizes 2025-01-29T16:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/gut-microbiota-research-in-sepsis-reveals-new-therapeutic-targets-and-biomarkers 2025-01-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-microbiota-research-in-sepsis-reveals-new-therapeutic-targets-and-biomarkers 2025-01-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ind-approval-for-first-ever-umbilical-cord-blood-derived-allogeneic-car-t-therapy 2025-01-29T14:42:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ind-approval-for-first-ever-umbilical-cord-blood-derived-allogeneic-car-t-therapy 2025-01-29T14:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/uzedy-r-exceeds-sales-expectations-with-117m-revenue-in-first-full-year 2025-01-29T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uzedy-r-exceeds-sales-expectations-with-117m-revenue-in-first-full-year 2025-01-29T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/ocean-biomedical-secures-3-5m-nih-grant-to-advance-novel-malaria-vaccine-development 2025-01-29T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocean-biomedical-secures-3-5m-nih-grant-to-advance-novel-malaria-vaccine-development 2025-01-29T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-launches-75-4m-platform-trial-to-test-multiple-psp-treatments-with-focus-on-diversity 2025-01-29T14:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-launches-75-4m-platform-trial-to-test-multiple-psp-treatments-with-focus-on-diversity 2025-01-29T14:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/braf-status-and-response-kinetics-guide-first-line-immunotherapy-selection-in-advanced-melanoma 2025-01-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/braf-status-and-response-kinetics-guide-first-line-immunotherapy-selection-in-advanced-melanoma 2025-01-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-advances-early-pregnancy-screening-with-eight-week-nipt-study-results 2025-01-29T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-advances-early-pregnancy-screening-with-eight-week-nipt-study-results 2025-01-29T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-advances-phase-2a-trial-for-first-ever-neuropathic-corneal-pain-treatment 2025-01-29T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/okyo-pharma-advances-phase-2a-trial-for-first-ever-neuropathic-corneal-pain-treatment 2025-01-29T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-novel-inhaled-jak-inhibitor-frevecitinib-in-severe-asthma-treatment 2025-01-29T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-novel-inhaled-jak-inhibitor-frevecitinib-in-severe-asthma-treatment 2025-01-29T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-drug-application-for-novel-myopia-treatment-nvk002 2025-01-29T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-accepts-drug-application-for-novel-myopia-treatment-nvk002 2025-01-29T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/itm-s-novel-radiopharmaceutical-outperforms-everolimus-in-late-stage-gep-net-trial 2025-01-29T11:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-s-novel-radiopharmaceutical-outperforms-everolimus-in-late-stage-gep-net-trial 2025-01-29T11:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-commits-to-medicare-drug-price-negotiations-with-modified-approach 2025-01-29T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-commits-to-medicare-drug-price-negotiations-with-modified-approach 2025-01-29T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-spontaneous-urticaria-market-expected-to-reach-36-billion-by-2035-as-novel-targeted-therapies-transform-treatment-landscape 2025-01-29T10:00:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chronic-spontaneous-urticaria-market-expected-to-reach-36-billion-by-2035-as-novel-targeted-therapies-transform-treatment-landscape 2025-01-29T10:00:27+00:00 hourly 0.9 https://trial.medpath.com/news/montefiore-einstein-cancer-center-secures-prestigious-three-year-coc-accreditation-highlighting-excellence-in-research-and-care 2025-01-29T10:00:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montefiore-einstein-cancer-center-secures-prestigious-three-year-coc-accreditation-highlighting-excellence-in-research-and-care 2025-01-29T10:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-roche-s-novel-lipoprotein-a-blood-test-with-molar-unit-measurement 2025-01-29T09:50:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-roche-s-novel-lipoprotein-a-blood-test-with-molar-unit-measurement 2025-01-29T09:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/teva-pharmaceutical-reports-strong-q4-revenue-but-stock-drops-on-conservative-2025-guidance 2025-01-29T09:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-pharmaceutical-reports-strong-q4-revenue-but-stock-drops-on-conservative-2025-guidance 2025-01-29T09:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-analysis-shows-extended-disease-progression-free-time-in-als-patients-using-radicava 2025-01-29T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-analysis-shows-extended-disease-progression-free-time-in-als-patients-using-radicava 2025-01-29T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-track-status-granted-to-vicore-s-novel-ipf-drug-buloxibutid 2025-01-29T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-track-status-granted-to-vicore-s-novel-ipf-drug-buloxibutid 2025-01-29T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/minnesota-oncology-leverages-value-based-care-experience-in-eom-transition 2025-01-29T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minnesota-oncology-leverages-value-based-care-experience-in-eom-transition 2025-01-29T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/tme-pharma-partners-with-aimed-analytics-to-advance-ai-driven-cancer-drug-development 2025-01-29T07:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tme-pharma-partners-with-aimed-analytics-to-advance-ai-driven-cancer-drug-development 2025-01-29T07:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/teva-reports-strong-q4-2024-results-exceeds-revenue-expectations-with-promising-pipeline-progress 2025-01-29T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-reports-strong-q4-2024-results-exceeds-revenue-expectations-with-promising-pipeline-progress 2025-01-29T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/mizuho-securities-maintains-hold-rating-on-neurocrine-as-osavampator-development-faces-timeline-uncertainties 2025-01-29T06:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mizuho-securities-maintains-hold-rating-on-neurocrine-as-osavampator-development-faces-timeline-uncertainties 2025-01-29T06:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/network-meta-analysis-reveals-comparable-efficacy-among-leading-chronic-constipation-treatments 2025-01-29T05:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/network-meta-analysis-reveals-comparable-efficacy-among-leading-chronic-constipation-treatments 2025-01-29T05:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-expert-outlines-strategies-to-balance-cancer-drug-costs-and-supply-chain-stability 2025-01-29T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-expert-outlines-strategies-to-balance-cancer-drug-costs-and-supply-chain-stability 2025-01-29T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/icmr-launches-large-scale-bcg-vaccine-trial-in-adults-for-tb-control 2025-01-29T04:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icmr-launches-large-scale-bcg-vaccine-trial-in-adults-for-tb-control 2025-01-29T04:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/ator-1017-shows-promising-safety-profile-and-early-efficacy-in-advanced-cancer-trial-published-in-jitc 2025-01-29T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ator-1017-shows-promising-safety-profile-and-early-efficacy-in-advanced-cancer-trial-published-in-jitc 2025-01-29T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-data-quality-hinges-on-site-level-management-experts-emphasize-at-oct-medical-devices-2025 2025-01-29T03:55:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-data-quality-hinges-on-site-level-management-experts-emphasize-at-oct-medical-devices-2025 2025-01-29T03:55:20+00:00 hourly 0.9 https://trial.medpath.com/news/t-dm1-shows-mixed-results-in-phase-2-trial-for-her2-biliary-tract-cancer 2025-01-29T03:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t-dm1-shows-mixed-results-in-phase-2-trial-for-her2-biliary-tract-cancer 2025-01-29T03:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/safety-concerns-mount-as-alzheimer-s-drug-leqembi-linked-to-patient-death 2025-01-29T03:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/safety-concerns-mount-as-alzheimer-s-drug-leqembi-linked-to-patient-death 2025-01-29T03:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/australia-approves-syfovre-as-first-treatment-for-geographic-atrophy-offering-hope-to-75000-patients 2025-01-29T03:02:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-approves-syfovre-as-first-treatment-for-geographic-atrophy-offering-hope-to-75000-patients 2025-01-29T03:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/europe-s-premier-biomarker-companion-diagnostics-summit-returns-to-london-in-2025 2025-01-29T02:30:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/europe-s-premier-biomarker-companion-diagnostics-summit-returns-to-london-in-2025 2025-01-29T02:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/eversana-and-lyfegen-form-strategic-alliance-to-transform-global-drug-pricing-and-access 2025-01-29T02:26:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eversana-and-lyfegen-form-strategic-alliance-to-transform-global-drug-pricing-and-access 2025-01-29T02:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-reports-mixed-phase-ii-results-for-sirexatamab-in-gastrointestinal-cancers 2025-01-29T02:13:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-reports-mixed-phase-ii-results-for-sirexatamab-in-gastrointestinal-cancers 2025-01-29T02:13:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-allogene-s-novel-dual-target-car-t-therapy-for-autoimmune-disease-trial 2025-01-29T02:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-allogene-s-novel-dual-target-car-t-therapy-for-autoimmune-disease-trial 2025-01-29T02:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-expands-veterans-access-to-novel-nk-cell-therapy-trial-for-metastatic-prostate-cancer 2025-01-29T02:03:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-expands-veterans-access-to-novel-nk-cell-therapy-trial-for-metastatic-prostate-cancer 2025-01-29T02:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-acquires-global-rights-to-promising-depression-drug-osavampator-from-takeda 2025-01-29T02:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-acquires-global-rights-to-promising-depression-drug-osavampator-from-takeda 2025-01-29T02:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/sab-142-shows-promising-safety-profile-in-phase-1-trial-for-type-1-diabetes-treatment 2025-01-29T02:02:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sab-142-shows-promising-safety-profile-in-phase-1-trial-for-type-1-diabetes-treatment 2025-01-29T02:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/cd39-targeted-therapies-pipeline-expands-over-15-candidates-in-development-with-first-approval-expected-by-2029 2025-01-29T02:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cd39-targeted-therapies-pipeline-expands-over-15-candidates-in-development-with-first-approval-expected-by-2029 2025-01-29T02:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/itm-11-achieves-breakthrough-in-phase-3-trial-radiopharmaceutical-outperforms-standard-therapy-for-gep-nets 2025-01-29T02:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-11-achieves-breakthrough-in-phase-3-trial-radiopharmaceutical-outperforms-standard-therapy-for-gep-nets 2025-01-29T02:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/aha-advisory-evt-shows-promise-in-large-core-stroke-treatment-six-clinical-trials-reveal 2025-01-29T00:37:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aha-advisory-evt-shows-promise-in-large-core-stroke-treatment-six-clinical-trials-reveal 2025-01-29T00:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-online-lifestyle-intervention-shows-promise-in-reducing-cognitive-decline-risk 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-online-lifestyle-intervention-shows-promise-in-reducing-cognitive-decline-risk 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/avidity-biosciences-secures-345m-following-promising-duchenne-muscular-dystrophy-trial-results 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avidity-biosciences-secures-345m-following-promising-duchenne-muscular-dystrophy-trial-results 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/mirage-trial-demonstrates-promise-of-mri-guided-sbrt-in-reducing-prostate-cancer-treatment-toxicity 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirage-trial-demonstrates-promise-of-mri-guided-sbrt-in-reducing-prostate-cancer-treatment-toxicity 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-s-20-year-brain-study-reveals-early-disease-markers-seeks-diverse-participation 2025-01-28T22:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-s-20-year-brain-study-reveals-early-disease-markers-seeks-diverse-participation 2025-01-28T22:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-injectable-hydrogel-shows-promise-in-rapidly-strengthening-osteoporotic-bones 2025-01-28T21:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-injectable-hydrogel-shows-promise-in-rapidly-strengthening-osteoporotic-bones 2025-01-28T21:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approval-of-ritlecitinib-marks-new-era-in-adolescent-alopecia-areata-treatment 2025-01-28T20:20:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approval-of-ritlecitinib-marks-new-era-in-adolescent-alopecia-areata-treatment 2025-01-28T20:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-instylla-s-novel-tembo-embolic-system-for-vascular-embolization 2025-01-28T19:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-instylla-s-novel-tembo-embolic-system-for-vascular-embolization 2025-01-28T19:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-q1-q2-2025-pipeline-eight-critical-infectious-disease-products-under-review 2025-01-28T19:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-q1-q2-2025-pipeline-eight-critical-infectious-disease-products-under-review 2025-01-28T19:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/veru-s-enobosarm-shows-promise-in-muscle-preservation-during-glp-1-weight-loss-despite-market-skepticism 2025-01-28T17:54:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veru-s-enobosarm-shows-promise-in-muscle-preservation-during-glp-1-weight-loss-despite-market-skepticism 2025-01-28T17:54:19+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-health-launches-groundbreaking-psilocybin-trial-for-treatment-resistant-depression 2025-01-28T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-health-launches-groundbreaking-psilocybin-trial-for-treatment-resistant-depression 2025-01-28T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-reports-mixed-results-from-cancer-clinical-trials 2025-01-28T17:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-reports-mixed-results-from-cancer-clinical-trials 2025-01-28T17:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-initiates-phase-3-program-for-novel-depression-drug-osavampator 2025-01-28T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-initiates-phase-3-program-for-novel-depression-drug-osavampator 2025-01-28T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/cagent-vascular-launches-500-patient-registry-to-evaluate-serranator-r-balloon-technology-for-pad-treatment 2025-01-28T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cagent-vascular-launches-500-patient-registry-to-evaluate-serranator-r-balloon-technology-for-pad-treatment 2025-01-28T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/uic-scientists-develop-safer-asparaginase-treatment-for-pediatric-leukemia 2025-01-28T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uic-scientists-develop-safer-asparaginase-treatment-for-pediatric-leukemia 2025-01-28T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/recent-advances-and-therapeutic-applications-of-fgf-based-drug-development 2025-01-28T15:46:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recent-advances-and-therapeutic-applications-of-fgf-based-drug-development 2025-01-28T15:46:16+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-reveals-widespread-vitamin-d-and-micronutrient-deficiencies-in-type-2-diabetes-patients 2025-01-28T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-reveals-widespread-vitamin-d-and-micronutrient-deficiencies-in-type-2-diabetes-patients 2025-01-28T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/servier-to-present-case-for-novel-idh-mutant-glioma-drug-vorasidenib-at-ema-review 2025-01-28T15:18:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-to-present-case-for-novel-idh-mutant-glioma-drug-vorasidenib-at-ema-review 2025-01-28T15:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/four-major-fda-decisions-in-urology-expected-by-mid-2025-novel-therapies-for-cancer-and-utis-under-review 2025-01-28T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-major-fda-decisions-in-urology-expected-by-mid-2025-novel-therapies-for-cancer-and-utis-under-review 2025-01-28T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/telotristat-ethyl-shows-promise-in-managing-weight-loss-for-metastatic-pancreatic-cancer-patients 2025-01-28T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telotristat-ethyl-shows-promise-in-managing-weight-loss-for-metastatic-pancreatic-cancer-patients 2025-01-28T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-launches-global-platform-to-accelerate-tuberculosis-treatment-trials 2025-01-28T14:49:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-launches-global-platform-to-accelerate-tuberculosis-treatment-trials 2025-01-28T14:49:46+00:00 hourly 0.9 https://trial.medpath.com/news/atalanta-therapeutics-secures-97m-series-b-to-advance-cns-targeted-rnai-therapies 2025-01-28T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atalanta-therapeutics-secures-97m-series-b-to-advance-cns-targeted-rnai-therapies 2025-01-28T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-enhertu-approval-for-most-common-form-of-breast-cancer 2025-01-28T14:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-enhertu-approval-for-most-common-form-of-breast-cancer 2025-01-28T14:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/helicore-biopharma-launches-with-65m-to-develop-novel-gip-targeting-obesity-treatment 2025-01-28T14:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helicore-biopharma-launches-with-65m-to-develop-novel-gip-targeting-obesity-treatment 2025-01-28T14:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/persephone-biosciences-completes-enrollment-for-landmark-microbiome-diet-study-in-colorectal-cancer-prevention 2025-01-28T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persephone-biosciences-completes-enrollment-for-landmark-microbiome-diet-study-in-colorectal-cancer-prevention 2025-01-28T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sirexatamab-shows-promising-35-response-rate-in-second-line-colorectal-cancer-trial 2025-01-28T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirexatamab-shows-promising-35-response-rate-in-second-line-colorectal-cancer-trial 2025-01-28T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-1-shows-complete-reversal-of-oxidative-stress-in-breakthrough-preclinical-study 2025-01-28T13:18:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telomir-1-shows-complete-reversal-of-oxidative-stress-in-breakthrough-preclinical-study 2025-01-28T13:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-s-grant-freeze-imperils-591-billion-in-federal-medicaid-funding 2025-01-28T12:57:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-s-grant-freeze-imperils-591-billion-in-federal-medicaid-funding 2025-01-28T12:57:16+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-seeks-nmpa-approval-for-advanced-prosense-cryoablation-system-in-china 2025-01-28T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icecure-seeks-nmpa-approval-for-advanced-prosense-cryoablation-system-in-china 2025-01-28T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-launches-groundbreaking-neural-cell-therapy-trial-for-drug-resistant-epilepsy 2025-01-28T12:27:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-launches-groundbreaking-neural-cell-therapy-trial-for-drug-resistant-epilepsy 2025-01-28T12:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-dual-designations-to-seed-s-novel-molecular-glue-for-rare-pediatric-cancers 2025-01-28T12:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-dual-designations-to-seed-s-novel-molecular-glue-for-rare-pediatric-cancers 2025-01-28T12:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/gossamer-bio-to-present-seralutinib-data-for-pah-treatment-at-pvri-2025-congress 2025-01-28T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gossamer-bio-to-present-seralutinib-data-for-pah-treatment-at-pvri-2025-congress 2025-01-28T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/walden-biosciences-strengthens-board-with-appointment-of-rare-disease-expert-howard-mayer 2025-01-28T12:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/walden-biosciences-strengthens-board-with-appointment-of-rare-disease-expert-howard-mayer 2025-01-28T12:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-halts-gastric-cancer-program-after-phase-2-trial-disappointment 2025-01-28T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-halts-gastric-cancer-program-after-phase-2-trial-disappointment 2025-01-28T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sotrovimab-shows-targeted-efficacy-in-covid-19-patients-with-high-viral-loads-recovery-trial-finds 2025-01-28T11:42:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sotrovimab-shows-targeted-efficacy-in-covid-19-patients-with-high-viral-loads-recovery-trial-finds 2025-01-28T11:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-annual-wellness-visit-program-set-for-major-expansion-in-2025 2025-01-28T11:30:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-annual-wellness-visit-program-set-for-major-expansion-in-2025 2025-01-28T11:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-spa-agreement-for-descartes-08-phase-3-trial-in-myasthenia-gravis 2025-01-28T11:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-spa-agreement-for-descartes-08-phase-3-trial-in-myasthenia-gravis 2025-01-28T11:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/corsair-pharma-adopts-instantgmp-s-digital-platform-to-advance-pah-treatment-development 2025-01-28T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corsair-pharma-adopts-instantgmp-s-digital-platform-to-advance-pah-treatment-development 2025-01-28T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-dmd-treatment-shows-promising-results-in-clinical-trial 2025-01-28T10:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-dmd-treatment-shows-promising-results-in-clinical-trial 2025-01-28T10:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trials-should-be-viewed-as-standard-care-option-not-last-resort-experts-emphasize 2025-01-28T10:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trials-should-be-viewed-as-standard-care-option-not-last-resort-experts-emphasize 2025-01-28T10:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/larsucosterol-shows-promising-90-day-mortality-reduction-in-phase-2b-alcohol-associated-hepatitis-trial 2025-01-28T10:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/larsucosterol-shows-promising-90-day-mortality-reduction-in-phase-2b-alcohol-associated-hepatitis-trial 2025-01-28T10:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-noncompliance-notice-over-clinicaltrials-gov-reporting-failure-signals-stricter-enforcement 2025-01-28T09:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-noncompliance-notice-over-clinicaltrials-gov-reporting-failure-signals-stricter-enforcement 2025-01-28T09:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/grove-ai-revolutionizes-clinical-trial-recruitment-with-ai-agent-grace 2025-01-28T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grove-ai-revolutionizes-clinical-trial-recruitment-with-ai-agent-grace 2025-01-28T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-endorses-macustar-s-novel-amd-assessment-methods-in-landmark-clinical-study 2025-01-28T09:04:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-endorses-macustar-s-novel-amd-assessment-methods-in-landmark-clinical-study 2025-01-28T09:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/lanifibranor-shows-promise-in-mash-patients-with-type-2-diabetes-legend-trial-results 2025-01-28T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lanifibranor-shows-promise-in-mash-patients-with-type-2-diabetes-legend-trial-results 2025-01-28T09:04:05+00:00 hourly 0.9